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ABSTRACT
BACTERIAL CLONING AND EXPRESSION OF BRCA2 ENCODED PROTEINS.
Emre Sayan
M S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August 1997, 109 pages.
Breast cancer is known to be the most common cancer among women in the 
world. It is assumed that one in ten women will develop breast cancer till the age 80. 
Heredity is the major risk determinant in breast cancer. 30% of the women with breast 
cancer have a positive family history and 10% of women is defined to have high risk of 
early onset breast cancer who have multiple family members of breast and ovarian 
cancer. A novel breast cancer susceptibility gene, BRCA2 was confirmed to account 
more than 40% of the mutations in familial breast cancer patients. BRCA2 tumor 
supressor gene encodes a 3418 amino acid protein with little or no homology to other 
known proteins. There is no significant data concerning the cellular functions of 
BRCA2 and many facts about BRCA2 are waiting to be uncovered. The gaps in the 
knowledge about BRCA2 must be filled by generating new points of views and 
technical approaches. Such studies require the cloning of BRCA2 and the presence of 
purified protein products. In this study we cloned a fragment of exon 11 and exons 19 
to 27 as 2 overlapping fragments. Since more than 80% of the mutations result in the 
loss of the C-terminal of the protein and produce cancer phenotype, we expressed and 
purified the extreme C-terminus of the BRCA2 protein.
ÖZET
BRCA2 GENİNİN BAKTERİYE KLONLANIP EKSPRESYONU
Emre Sayan
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 1997, 109 sayfa.
Meme kanseri dünyada kadınlar arasında en yaygın görülen kanserdir. Her on 
kadından birinin 80 yaşından önce meme kanserine yakalanacağı düşünülmektedir. 
Kalıtım meme kanseri riskinin en önemli belirleyicisidir. Her on kadından üçünün 
ailesinde meme kanseri geçmişi vardır ve her on kadından birinin ailesinde birden çok 
meme ve över kanserli birey olduğu samimaktadır. BRCA2 yeni bulunmuş bir kansere 
yatkınlık genidir ve ailesel meme kanserlerinde yüzde kırk ihtimalle mutasyona uğrar. 
BRCA2 tümör baskılayıcı geni, hiçbir bilinen genle benzerliği olmayan 3418 aminoasit 
uzunluğunda bir protein kodlar. Şu ana kadar BRCA2 proteininin fonksiyonlan ile ilgili 
tatmin edici bilgiler elde edinilememiştir ve bu genin özellikleri keşfedilmeyi 
beklemektedir. Bu genle ilgili eksiklikler, yeni düşünceler ve yeni teknik yaklaşımlarla 
bulunulabilir. Bu tip çalışmalar için BRCA2 geninin klonlanması ve proteininin 
saflaştıniması gerekmektedir. Biz bu çalışmada BRCA2 geninin ekzon 1 Tinden bir 
parça ve ekzon 19'dan 27'ye kadar olan kısmı 2 birleştirilebilir parça olarak klonladık. 
BRCA2 genindeki mutastonlann çoğu karboksil ucu olmayan proteinler oluşturduğu ve 
kansere sebeb olduğu için karboksil uç kısmımn proteinini bakteride ürettik ve 
saflaştırdık.
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1- INTRODUCTION
1.1- Quick review on Breast Cancer
Breast cancer is the most frequent cancer in women worlwide. It is estimated 
that one of each ten women will develop breast cancer in their lifetime in the 
industrialized countries. In the United States, more than 180000 new cases were 
observed in 1996 and 45000 women had died of breast cancer (Parker ei al. 1996). 
Breast cancer is 100 times less frequent in men and it is also very rare in young 
women (<20 years). Its frequency increases progressively from 25 to 45 years of age, 
it stabilizes around 55 years, then increases abruptly in older age. About the 85 % 
breast cancers occur after 40 years of age. Genetic alterations that take place in the 
progression from normal breast epithelium to metastatic carcinoma are summarized in 
figure 1.
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Figure 1: Genetic alterations that take place in the progression from normal breast 
epithelium to metastatic carcinoma
Breast cancer is a tumor of the mammary gland. The anatomy of breast 
is shown in figure 2. The breast is composed of a duct epithelium with surrounding 
fibrous stroma. The ducts and lobules, together with interlobular fibrous tissue are 
called breast parenchyme. This parenchyme is diffusely distributed within the adipose 
tissue of breast. With the onset of menarche, pituitary-ovarian hormones allow the 
differentiation and development of terminal duct lobular units. Unlike the intermediate 
duct systems which are stable and unaffected through hormonal fluctuations, the 
terminal lobular units are dynamic structures and undergo marked alterations during 
regular menstrual cycles. The 17ß-estradiol (active estrogen) and progesterone play a 
critical role in the physiological regulation of mammary gland. Estrogen acts mostly 
on the terminal ducts and induce mitotic activity of epithelial cells. The progesterone, 
which is secreted periodically during the second phase of menstrual cycle, blocks 
mitotic activity induced by estrogens.
Breast tumors are classified as benign and malignat tumors. Among benign 
tumors, fibroadenomas are the most frequent forms which develop before the age of 
30. They are chracterized by a glandular proliferation with a variable fibrous 
component. More than 98% of malignant breast tumors are carcinomas. In situ 
carcinomas or non infiltrating carcinomas occur in the epithelium of ducts or the 
lobuls. They do not infiltrate the neighbouring connective tissue. They represent about 
7% of breast carcinomas. Infiltrating or invasive carcinomas are mostly ‘ductal 
carcinomas’ (70%). Paget disease is a carcinoma composed of large tumor cells 
infiltrating the epidermis of the nipple. It represents about 2% of breast cancers and it 
is associated to another mammary carcinomas (Rubin E. and Färber JL. 1988 ).
The anatomy o f the breast is shown in figure 2,
Figure 2: The anatomy of the breast.
Environmental, hormonal and hereditary factors contribute to the high 
frequency of beast cancer in women (Daudt. et al. 1996). Some of the risk factors 
associated with breast cancer risk are summarized in table 1.
TabIe-1: Risk Factors associated with the carcinoma of breast.
1. 2 Etiology of Breast Cancer
FACTOR RELATIVE RISK
Family History
Primary relative 1.2-3.0
PostmenapausaJ unilateral 1.5
Premenapausal bilateral 8.5-9.0
Menstrual History
Age at menarche<12 years 1.3
Age at menapause>55 years 1.48-2.0
Preganacy
First child after 35 2.0-3.0
Nulliparous 3.0
Other Breast Diseases (including hyperplasia and in situ 
carcinoma)
0.9-10
1. 2-1 Hereditary predisposition to breast cancer:
About one third of women with breast cancer have a positive family history of 
one or more first degree relatives (Marcus et al. 1996) and one tenth of all breast 
cancers are attributed to familial breast cancer, which is seen in high risk families. 
There are two breast cancer succeptibility genes identified (BRCAl and BRCA2) that 
define more than 80% of the familial breast cancer cases after age 80 (Ford et a l
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1995). Considering the 10% lifetime risk of breast cancer, 10% risk of familial breast 
cancer among all breast cancers and 80% of the mutations to be in BRC genes, one in 
120 women is in access of breast cancer after the age of 80 due to BRC genes.
1. 2-2 Environmental Factors:
Diet and exercise: Sevaral factors including socioeconomic and nutritional status 
were underlined to be associated with increased risk of breast cancer. Because of 
improved health conditions in industrialized countries, the average age of menarche 
decreased whereas the average age of menopause increased. The breast epithelium is 
mitoticly active during this period, so it is vulnerable to carcinogenic influences for a 
longer time period. Women, who had migrated to US. from countries where the 
breast cancer incidence is low, quickly attain a breast cancer risk close to the 
inhabitants of the area (Rubin E. and Färber JL. 1988). Statistical studies defined that 
dietary intake monounsaturated and polyunsaturated fats, might reduce the risk of 
premenopausal bilateral breast cancer (Witte et a l 1997). Olive oil and milk 
consumption were observed to be associated with decreased risk of breast cancer 
(Knekt et al. 1996) as well as exercise and daily uptake of vitamin A (Bertstein et al. 
1994, Kushi etal.\996).
Alcohol and smoking: In 38 statistical epidemiologic studies it was shown that 
women drinking three or more drinks daily had a 40% higher risk of breast cancer 
when compared with non-drinkers . The risk factor is most elevated at around age 50 
(Homberg et al. 1995). When smoking is concerned, there is no direct evidence 
between breast cancer, but typical smoking related DNA adducts were seen in the 
tissue samples of smokers and (possibly passive but) non-smokers (Li et al. 1996).
Age: Strong statistical data describing the cumilative breast cancer risk due to 
mutations in BRC A1 (calculated by Breast Cancer Linkage Consortium) and due to 
both BRCAl and BRCA2 mutations (Struewing et al. 1997) were available and 
shown in table 2 (Easton e/a/. 1997).
Table-2: Age versus cumilative breast cancer risk in familial breast cancer patients.
Based on the fact that both genetic and environmental factors play a role in 
breast cancer, the tumors can be classified as familial and non-familial. Since the 
familial breast cancer is only 5-10% of total breast cancers and there is a gradual 
increase in breast cancers since 1940, environmental factors can be thought to play a
bigger role, but the most important thing concerning this fact is the genes that couse 
sporadic and familial breast cancer are mostly common.
There are 3 genes known to contribute both familial and sporadic breast 
cancer; p53, BRCAl and BRCA2.
1.3 Molecular Basis of Breast Cancer
As many cancers, breast cancer is a multi-factorial and multi-step disease. 
Hereditary and somatic mutations on different genes were shown to define the multi- 
step nature of breast cancer. Familial and sporadic breast cancer show a great 
heterogeneity in terms of age of onset, excess of bilaterality, patterns with multiple 
primary cancers and age. Some of these factors are linked to some diseases like 
hereditary breast-ovarian cancer syndrome and Li-Fraumeni (SLBA) syndrome. The 
genetic heterogeneity of breast cancer is illustrated in figure 3.
□  Cowden's disease
□  SLBA syndrome
■ Site specific breast cancer
□  Breast/Gastrointestinal cancer
O Extraordinarily early onset 
breast cancer
O Breast and miscelaneous 
tumors
□  Polygenic
□  Sporadic
■ Breast/Ovarian cancer
Figure-3: Genetic heterogeneity of breast cancer (Lynch et al. 1994).
synthesis at Gl/S phase of cell cycle. In a study of n=223, loss of Rb expression was 
defined at 21% ofprimary breast tumors (Anderson et a/. 1996).
P53 ; p53 gene which is considered to be the guardian of the genome, is the 
most common mutated TSG in all types of cancers (~40% average). Of about 6.5 
million cancer cases worldwide each year, 2.4 million tumors were estimated to 
contain p53 mutation. It is also very important to consider that breast cancer is more 
frequent in developed countries, being the most common in US. The estimated 
incidence of breast cancers in US. with p53 mutations is 25-30% (44000 in 183000 
new breast cancer cases) in 1995 (Harris C. Curtis 1996).
1.3-2 Oncogenes:
BCLl (cyclin D l) ; Cyclins are common markers for breast cancer 
progression. Especially cyclin E and Dl (BCLl) expressions were seen to be 
elevated in such tumors. Immunohistochemical staining of cyclin D is a good 
technique since the detection of BCLl gene amplification may not result in high 
expression, but uncontrolled expression. BCLl overexpression is seen at 
approximately 30% of breast cancers (Gillett etal. 1994).
BCL2 : This is a gene which belongs to a family that is involved in the control 
of cell fate. BCL2 is an inhibitor of cell death and acts as an antagonist of bax gene, 
which encodes a protein inducing programmed cell death. In a recent study the 
expression pattern of BCL2 in breast carcinoma was investigated and found to be 
altered in 33% of them (by immunohistochemical methods), especially in tumors 
where p53 expression was altered (Siziopikou et al. 1996). In another study BCL2 
and p53 mutations were used to differentiate male and female breast cancer. It was 
shown that p53-/BCL2+ phenotype is more associated with male breast cancer 
(Weber-Chappuis. e/a/. 1996).
ERB-B2 : ERB-B2 (neu/Her-2) is a cell surface growht factor receptor with 
receptor tyrosine kinase activity and its overexpression is an indicator of tumor 
progression. In a controlled study of 295 primary breast tumors, it was shown to be 
amplified in 28% of the cases (Bems et al. 1995 )
MDM2 : This cellular oncogene may play a role in tumorigenesis by 
inactivating the p53 protein which was defined as the guardian of the genome. Mdm2 
expression levels were defined to be elevated up to 8 folds in 4 to 9% of breast 
tumors with a decreased imuunostaining of p53 (McCann et al 1995, Marchetti et al. 
1995).
MYC : The myc proto-oncogene is first chracterized as a viral homologue of 
a cellular protein and it is essential for transcriptional activation of DNA polymerase 
subunits and cyclins to allow the cell to propogate through cell cycle. Its 
amplification and overexpression is seen in about 17% of breast tumors (Bems et 
а/. 1995). Мус gene is amplified in about 15% (range 6-32%) breast cancer cases 
(Marc etal. 1993).
1.4 Hereditary Breast Cancer Genes
BRC genes and p53 : The p53 tumor supressor gene, which is 
localized to 17p encodes 53 kDa phosphoprotein with multiple important fianctions 
concerning cell fate. These functions include cell cycle arrest, apoptosis and induction 
of DNA damage response genes upon DNA damage (Vogelstein et al. 1992). The 
loss of functional p53 produces genetic instability and being prone to new mutations. 
This is why p53 mutations were seen more than 40% of all tumors (Harris C. Curtis
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1996). In table 3, the results otained by detection of LOH at p53 locus in breast 
cancer (Lindblom A., et al. 1993) were summarized.
Table-3: Loss of heterozygosity at p53 locus.
Loss of Heterozygosity at p53 locus
Breast tumors from families of type
Breast cancer families
Cancer families
Predominant breast cancer mean age<50
Predominant breast cancer mean age>50
Breast cancer and other tumors mean age<50
Breast cancer and other tumors mean age>50
LOH in p53 locus :
3/13
1/3
4/9
1/8
2/5
2/6
25-30%
30-35%
45-50%
10-15%
40%
30-35%
These and similar type of experiments showed that there are 30% LOH at p53 
locus at breast cancer families. The incidence gets higher especially in breast cancers 
occuring before the age 50 (50%), which are called as familial breast breast cancer. 
Germline p53 mutations were detected in many families with Li-Fraumeni syndrome 
(LFS). The tumors associated with LFS are breast cancer, osteosarcoma, soft tissue 
sarcoma, brain tumors and leukemia. Several studies conformed the increased 
incidence of breast cancer in LFS families (Malkin et al. 1990). Interestingly, different 
investigations done in defining the mutation frequency of p53'in male breast cancer 
had conflicting results. The percentage of loss of functional p53 changes from 5-10% 
(Weber-Chappu et al. 1996) to 40% (Anelli et al 1995, Soussi et al. 1996). These
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results may indicate a probable interaction of p53 with BRCAl or BRCA2 since 
BRCA2 mutations were most commonly seen in families with a positive history of 
male breast cancer unlike BRCAl.
When BRC genes are concerned it is possible to say that they account for 
80% of the cases for the breast cancer patients in high risk families. About one third 
of women with breast cancer have a positive family history of one or more first degree 
relatives with the disease. A smaller fraction (5-10%) of breast cancer is hereditary 
breast (and ovarian) cancer and strictly defined to be :
• Having 3 or more first degree relatives with breast and/or at least 2 ovarian or 
male breast cancer cases in the family.
• The age of onset of the disease must be less than 50.
BRC genes were proven to be very important in the development of 
familial breast cancer but it is possible that they have also a role in sporadic breast 
cancer. The experiments done for defining the involvement of BRCAl in sporadic 
breast tumors showed that BRCAl is rarely involved in sporadic breast tumors but in 
sporadic ovarian tumors (Merajver et al. 1995, Cropp et al. 1994). The involvement 
of BRCA2 in sproradic breast tumors is not well defined for now. Allelic imbalance 
(Al) was found at 13q loci at 52-63% of 78 sporadic primary breast tumors, 9 of 
which showed Al at BRCA2 locus but not Retinobastoma (Rb) and 6 of which 
showed Al at Rb locus but not in BRCA2 (Hamann et al. 1996). This data suggested 
that Rb and BRCA2 are distinct targets in sporadic breast cancer. In a more definitive 
study, Lancaster et al. (1996) found 2 mutations in BRCA2 gene, which of 1 was a 
sporadic missence mutation (n=70) in primary breast tumors. The mutation rate of 
BRCA2 in sporadic ovarian cancer seems to be higher. Foster et al. (1996) defined 2 
sporadic and 2 germline mutations in 55 primary ovarian tumors. These results
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indicate that the mutation incidence of BRCA2 in sporadic breast and ovarian tumors 
is significantly higher than BRCAl, but still rare.
High risk breast cancer families helped the identification of first breast cancer 
succeptibility gene (BRCAl) in 1990 (Hall et a l 1990) which is cloned in 1994 (Miki 
et a/. 1994). The cloning strategy of BRCAl required extensive study on 23 high risk 
families with 146 cases of breast cancer. The families include individuals with sporadic 
and familial breast cancer with early onset of the disease and bilateral progression as 
well as late onset (probably some sporadic cases). Hall et al. (1990) found a LOD 
score of 5.98 for linkage of breast cancer succeptibility in early onset families to 
marker D17S74, which is located at 17q21. Negative LOD scores were observed in 
families with late onset disease. Candidate genes included HER2 (Erb-b2), a cluster of 
homeo box 2 genes, retinoic receptor alpha and estradiol-17-beta-dehydrogenase. 
Claus et al. (1991) reported the same location harboring a rare autosomal dominant 
allele (q=0.0033) for succeptibility to breast cancer. This work based on a data set of 
4730 histologically confirmed breast cancer patients aged 20-54 and 4688 controls. 
The cumilative lifetime risk of breast cancer for carriers of this allele was turned out 
to be 92% and 10% for non-carriers, which was quite close to the lifetime risk of 
BRCAl defined by current studies. Studies done in families with hereditary breast and 
ovarian cancer showed that LOH in this locus was at 70% (Narod et al. 1991, Lynch 
HT and Watson P. 1992).
Although p53, BRCAl and BRCA2 may account for a small fraction 
mutations in all breast cancer (10 % of all cases), their trait of inheritance is highly 
penetrant and autosomal dominant in Hereditary Breast and Ovarian Cancers 
(HBOC).
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1.5 BRCA2
1.5-1 Review on BRCA2
A small portion of breast cancers, especially that occured at a young age is 
specifically due to mutations at autosomal dominant inherited genes. Germline 
mutations in p53 gene (Malkin et al 1990) and BRCAl (Gayther et al. 1995) were 
defined to confer the 10% to 55% of the breast and ovarian cancers in predisposed 
families. One of the probable remaining breast cancer succeptibility genes, BRCA2 
waited to be discovered until late 1994 (Wooster et al. 1994). In figure 4 the 
ideogram of human chromosome 13 is shown.
13  1 3 ( ^ 3
P 12 =
11.2 :·??;-
32
33
34
Figure-4: Ideogram of chromosome 13
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For localizing BRCA2, a genomic linkage search was performed in 15 
families with multiple cases of early-onset breast cancer that were not linked to 
BRCAl. Out of the 162 total cancer cases there were 8 male breast cancers and 16 
ovarian cancers. Families were genotyped with microsatellite repeat markers and the 
second breast cancer succeptibility gene was roughly localized at a 6-cM interval on 
chromosome 13ql2-ql3, around marker D13S260. This study defined a 87% risk of 
breast cancer by the age 80, which is similar to BRCAl phenotype but unlike BRCAl, 
ovarian cancer risk associated with this loci is not as much. The fiirther localization is 
done by Schutte et al. (1995). They tried to define the fine LOHs in pancreatic 
adenocarcinomas using a new technique called representational difference analysis and 
showed a homozygous deletion in a 1-cM region of 13ql2.3. The presence of this 
deletion suggested the presence of a TSG within the 6-cM region which was 
identified as BRCA2 locus. Localization of a new TSG further increased the effort on 
chracterization the gene and mutations at that loci and Gudmundsson et al. (1995) 
reported involvement of LOH in different tumor types in 5 families of 50 members 
that show strong evidence of linkage to BRCA2. These tumors (58 sample from 50 
patients) include mostly female breast cancer and LOH is defined in 28 of 33 breast 
tumors. Seven prostate tumors, six ovarian, one colon, one cervical, one male breast 
and one ureter tumor from BRCA2 carriers were analyzed and all were defined to lose 
heterozygosity at BRCA2 locus, except one prostate and one ovary tumor. The high 
incidence of male breast cancer and the low incidence of ovarian carcinoma associated 
with this locus also proves the presence of a new breast cancer gene. Thorlasius et al. 
(1995) draw the attention to breast cancer risk of females in the families with male 
breast cancer. Familial susceptibility to early onset breast and ovarian cancer in 
women has been linked to BRCAl gene in some extent, but the-low frequency of male
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breast cancer risk in such families was also defined (Stratton et al. 1994). In 
localization studies of BRCA2, Wooster et al. (1994) defined a positive LOD score in 
BRCA2 linkage in families with female and male breast cancer. The work of 
Thorlasius et al. (1995) defined a definite linkage to BRCA2 locus in male breast 
cancer families, but interestingly there was no increase in female breast cancer. The 
fine localization of BRCA2 to 13ql2-ql3 was unexpectedly enhanced by the work of 
Shutte et al. (1995) who defined a homozygous somatic deletion at this region and 
narrowed down the region to 600kb around marker D13S171. Wooster et al. (1995) 
reported the identification of a gene that had six different germline mutations in breast 
cancer families that were likely be due to mutations in BRCA2. Each mutation was 
also confirmed to disturb the open reading frame of the transcriptional unit. Wooster 
et al. (1995) generated yeast artificial chromosome (YAC) and PI artificial 
chromosome (РАС) contigs to extend 700 kb centromeric and 300 kb telomeric to 
D13S171 and identified minimally overlapping 14 PACs. Transcribed sequences lying 
in these PACS were defined by either exon trapping or hybridization with 
complementary DNA and screened for crucial mutations like truncation or splice site 
destruction in breast cancer families showing linkage to BRCA2 (families including 
male breast cancer or families showing negative LOD score in BRCAl linkage). The 
definition of six disease associated mutations like truncation of the encoded protein 
showed the expressed sequences at that region belong to the second breast cancer 
susceptibility gene. With this approach a 7.3 kb cDNA is defined (including 300 bp of 
3 prime untranslated region) to encode 2239 aminoacids, which was not full BRCA2 
cDNA. The identified portion of BRCA2 showed no significant homology with any 
known proteins except a weak homology at residues 1783-1863, with BRCAl 
residues 1394-1474. The work done by Wooster et al. was completed by Tavtigian et
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al. (1996) and the complete coding sequence, exon-intron structure and the 
expression pattern of BRCA2 was examined. The features of BRCA2 defined by this 
study were as follows:
BRCA2 lies near the centre of a 1.4 megabase interval flanked by markers 
D13S1444 and D13S310. Translation of the cDNA starts at nucleotide 229 to 
encode for a 3418 aminoacid protein. Hybridization of the labeled cDNA revealed a 
ll-12kb transcript and high expression was detected in breast, testis and thymus 
with less amounts in spleen, lung and ovary. The identified cDNA was 11385bp 
without poly adénylation signal and poly A tail. When gene structure was concerned, 
cDNA and genomic sequences were compared. The gene was composed of 27 
exons and distributed over roughly 70kb of genomic DNA. Southern blot analysis 
revealed no close homologue of the gene in the human genome. The cDNA consists 
of >60% A/T unlike most of the human genes. There was a CpG rich region at the 
5 prime end of the gene suggesting a regulatory region, but there was no clue of a 
signal sequence or membrane spanning regions on the coding sequence. One of the 
unique property of BRC genes were revealed with this study; a huge exon 11, 3426 
bp for BRCAl and 4932 bp for BRCA2. BRCA2 protein was found out to be highly 
charged, roughly one quarter of all amino acids were acidic or basic. The discovery 
of BRCA2 allowed the comparison between BRC genes and define their role as a 
tumor supressor. Here are the similarities of BRC genes:
• Highly charged proteins
• Have a huge exon 11
• Distributed on a 70kb genomic DNA
• Translation starts at the second exon
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• Expression patterns are similar (highest in testis and breast)
• Most of the mutations destrupt the reading frame so produce early
termination of translation
• Unlike mammalian genes, they are A/T rich
Tavtigian et al. (1996) not only found out the features BRCA2 gene, but also 
screened 18 kindreds (for 9 kindreds exon 15 was not available) for germline BRCA2 
mutations to further define some mutations that disable the function of the protein, so 
understand the functional domains of this novel protein. Mutations were detected in 9 
of the 18 kindreds, and all except one seem to produce immature stop of translation. 
The exceptional mutation was a three base deletion at position 4132 (del thrl302), 
which didn’t alter the reading frame. This mutation was not observed in 36 other 
unrelated breast tumors and the function of thrl302 could not be determined. Most of 
the mutations detected in BRCA2 were microdeletions of 1-6 bp whereas point 
mutations and microinsertions dominate the mutation profile of BRCAl. There were 
also 9 polymorphisms, 2 in the 3 prime, 1 in the 5 prime untranslated region in 
BRCA2.
After the discovery of the gene, the attention was drawn on BRCA2 mutation 
profile to define early detection and prevention methods for breast cancer. Lancaster 
et al. (1996) screened entire gene using a combination of SSCA, denaturing gel 
deletion analysis and PTT techniques in primary breast and ovarian tumors. LOH was 
observed at 34 of breast and 18 of ovarian tumors but no mutation was identified in 
ovarian tumors and only 2 of the 70 breast tumors displayed a mutation. One of the 
mutations was a germline mutation that caused a frameshift (4710del AG) and the 
other one was a somatic missense mutation (Asp 3095 Glu) of unknown function. The 
results were similar to ones obtained in BRCAl in sporadic breast and ovarian tumors
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and the authors indicated the infrequent mutation of BRC genes in sporadic cases. 
Teng et al. (1996) had similar results. In this study, complete BRCA2 gene was 
screened for mutations in 12 different cell lines, representing different tumors. A 
germline mutation in a pancreatic carcinoma cell line was detected proposing a role to 
BRCA2 in that neoplasm. A more convincing experimental result came from Miki et 
al. (1996) in which the study was done in 100 sporadic Japanese breast cancer 
patients with no family history. One somatic missense (His 2415 Asn) and 2 germline 
frameshifl mutation were identified. One of the germline mutation was a 346 bp 
insertion to exon 22. A 64 bp polyadenylate tract a 8 bp duplication showed the 
presence of an active Alu element insertion at this site. The Alu element didn’t cause a 
frameshift mutation but terminated translation by an internal stop codon. The other 
germline mutation was a 4 bp deletion at codon 252, producing an early truncation.
Population-based studies define new mutations in BRCA2. Gudmundsson et 
al. (1996) reported the first study amond Icelandic population and showed a strong 
likage to BRCA2 region. The interesting point of the study was the same haplotype 
observed in 5 of the 7 families. Thorlacius et al. (1996) studied 21 Icelandic families 
which were selected on the basis of frequent breast cancer cases including male breast 
cancer. 16 of 21 families showed a strong linkage to BRCA2 locus. A common 
mutation of a 5 bp deletion at exon 9, starting at nucleotide 999 in codon 257 was 
found. This common mutation and the same haplotype suggests a founder effect. 999 
del 5 was also defined in different tumors such as prostate, pancreas, ovary, colon, 
thyroid, cervix and endometrium (Gudmundsson et al. 1996). Neuhausen et al. 
(1996) and Couch FJ. et al. (1996) reported a novel mutation in highly inbreed 
Ashkenazi Jewish population. This mutation was 6174 del T and the frequency of the
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mutation appeared to be 3 per 1000 in the general population. Six of 80 Ashkenazi 
Jewish women diagnosed with breast cancer before the age of 42 were heterozygous 
for the mutation (8%) and the non-Ashkenazi control group showed no sign of that 
mutation (n=93). In 2 of 27 additional Jewish families, in which breast cancer 
occurred at age 42-50 the same mutation was detected (7%). These results propose 
the recurrent BRCA2 mutation in an inbreed population resulting about a quarter of 
all familial breast cancers. The observations of Neahusen ei al. were partially refuted 
by Berman et al. (1996), who described the particular mutation to be encountered in 
Jewish and non-Jewish individuals. The study was done on 83 individuals with breast 
and 93 individuals with ovarian cancer and 6174 del T was observed in 8 patients 
(4.5%). 7 of the 8 patients were Ashkenazi origin but only 2 of them showed a 
common haplotype indicating several independent origins of this common mutation. 
Two more reports define the importance of revealing the specific mutations in specific 
populations like Ashkenazi Jews (Roa et al. 1996, Oddoux et al. 1996) and giving 
exact numbers for carrier frequency and penetrance of 6174 del T. It was supposed 
that the mutation was the most frequent mutant allele (carrier ffequency=1.52%) 
predisposing breast cancer among Ashkenazi Jews but the penetrance was not as high 
as the most frequent mutant allele of BRCAl (185 del AG) in this population. The 
relative risk of developing breast cancer with this mutation was calculated to be 9.2% 
by the age 42.
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In 1997, numerous studies were done to define the mutation profile of BRCA2 
in different populations. Most of these studies rely on high risk breast and/or ovarian 
families with male breast cancer (for BRCA2) except for the ones that family history 
is omitted. The general outcome of these reports on BRCAl and BRCA2 indicate that 
BRCAl mutations couse a higher percentage of breast and ovarian cancer in the 
world (Szabo Cl. and King MC, 1997), with the exception of some isolated 
populations like Icelanders. In the families with male breast cancer cases, BRCA2 
mutations predominate. This is also the case in U.S. extensive studies done in different 
ethnic groups, BRCA2 was defined to be responsible for 19% of familial male breast 
cancers but for a very small fraction of male breast cancer in the general population. 
Fewer number of mutations and the low penetrance of BRCA2 mutations, define a 
25% reduced risk for BRCA2 compared with BRCAl (except Iceland). In about 30% 
of high risk families there were no BRCAl or BRCA2 alterations detected. These 
included 3 of 4 Hungarian families with at least 6 cases of breast or ovarian cancer 
(Ramus et al. 1997) and 2 of 6 male breast cancer families and 15 of 23 female breast 
cancer families of midwestem American origin (Serova et al. 1997). The data led 
several groups to suggest the existence other BRC genes.
Most of the mutations in BRCA2 are microdeletions and microinsertions of 1- 
6 bp whereas there were very little missense and nonsense mutations. There are few, 
one aminoacid deletions (3 bp) suggesting the importance of specific aminoacids (see 
figure 5 and above). The general outcome of the mutations in BRCA2 is the immature 
stop of translation due to a ffameshift in the gene.
1.5-2 Known mutations in specific populations
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Except for a few, most of these studies were reviewed in Am. J. Hum. Genet, 
volume 60, 1997. In tables 4 and 5, the incidence and country specific distribution in 
various populations of BRCA2 mutations were summarized (Modified from Csilla I. 
Szabo and Mary-Claire King 1997).
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Table-4: BRCA2 mutation incidence in different countries.
POPULATION
No. of mutation/
No. of patients Reference (s)
Families with three or more 
cases of female breast 
and/or ovarian cancer:
Britain
Canada
Finland
France
Hungary
Iceland
Israel
Sweden and Denmark 
United States
25/290 (9%) 
8/49 (16%) 
8/100 (8%) 
14/77 (18%) 
4/32 (13%) 
7/11 (64%) 
8/34 (24%) 
12/106(11%) 
24/94 (25%)
Gayther et al. ( 1997)
Phelan et al. (1996)
Vehmanen e/a/. (1997) 
Serova-Sinilnikova et al. ( 1997) 
Ramus e/a/. (1997)
Thorlacius e/a/. (1996) 
Levy-Lahad et al. ( 1997) 
Hakansson e/ur/. (1997)
Couch et al. ( 1996), Serova et al. 
(1996, 1997), Tavtigian et al. 
(1996), Schubert étal. (1997)
Families with male and 
female breast cancer:
United States 12/64 (19%) Couch e/a/. (1996), Serovc
Hungary 2/6 (33%)
(1997)
Ramus e/a/. (1997)
Iceland 9/10 (90%) Thorlacius e/a/. (1996)
Breast and/or ovarian cancer
patients not selected for
family history
Iceland 42/497 (8%) Johannesdottir et al. (1996)
Israel 14/243 (6%) Abeliovich e/a/. (1997)
Japan 2/103 (2%) M ikie/a/. (1996)
Table 5: Specific BRCA2 mutations in specific populations.
BRC A2 mutations in breast and ovarian cancer families and patients
No of mutations
BRCA2
nucleotide
Exon change Brit. Fran. Hun. SweD. Fin. Ice. Isr. US. Can.
11 6503delTTT 5
11 5573delA* 2 1
11 3034del4 3 1 1 2
10 1529del4 1 1
10 2034insA 1 1
11 6174delT 1 1 11 5 1
2 277delAC 1 1
23 9326insA 1 1 1
11 4486delG 2
9 999del5 2 61
18 8555T->G 2
1-23 9346 (-2)A->G 2
9 982del4 3
20 8764delAG 2
Other 12 13 3 10 2 0 NT 19 3
Brit. : Britain, Fran.:France, Hun.:Hungary, SweD.:Sweeden and Denmark.
Fin.:Finland Ice.: Iceland Isr.:Israel, US.:United States Can.: Canada
*: This mutation was defined as 5573del/insA/AA NT: Not tested.
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Mutations characterised in BRCA2 gene
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1.5-3 Computer based studies
1.5-3-1 Homology with grauiu family, with BRCAl aud couserved 
iuterual repeats iu BRCA2
As a novel gene, identified by Wooster e/a/. (1995), BRCA2 was defined to 
confer no homology region with other known genes, except a weak homology at a 
restricted region (amino acids 1394-1474 of BRCAl and 1783-1863 of BRCA2) with 
an unknown function. A computer based study considering the function of BRCA2 
revealed the BRC genes to carry a granin domain ( Jensen et al. 1996). A perfect 
granin consensus was found in BRCAl at residues 1214-1223 and a match of six of 
seven constrained amino acids in BRCA2 at residues 3334-3344 was defined. Granins 
are proteins that assemble in the secretory vesicles and thought to help folding of 
other proteins. They are highly charged and share a 90% conserved granin box near 
their C-terminal just like BRCA2. Jensen et al. not only defined the presence of a 
homology region at C terminus of BRCA2, but also showed that BRCAl was 
localized to membrane fraction of cell lysate, in the secretory vesicles and Golgi body. 
The presence of a secreted tumor supressor gene is fascinating since it opens the way 
of variety therapeutic studies. However these speculations were ruled out by the 
discovery of a polymorphic stop codon leading to production of the protein without 
the granin domain which was fiilly functional (Mazoyer etal. 1996).
BRCA2, as a very big gene producing a 390 kd protein may have lots of 
functions. Such proteins produce the constructural framework of the cell, 
cytoskeleton. Although these proteins are very big, their aminoacid structure propose 
a modular structure of repeating domains which are essential for binding other 
proteins. Dystrophin can be a good example of such proteins having multiple copies
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of conserved motifs called spectrin like repeats and hinge sites. Expression pattern of 
BRCA2 defines a functional, rather than a structural role, but the functions of BRCA2 
is not identified for now. The work of Bork et al. (1996) showed the presence of 8 
conserved repeats in the exon 11 of BRCA2. The average of the lenght of these 
repeats were 60 (30-80) aminoacids and 13 of these residues in these repeats were 
80% conserved. One of the repeats even coincided with the BRCAl homology region 
which demonstrated the evolutionary importance of this domain. Also these modular 
regions were identified to confer homology with a C. elegans protein of unknown 
function and called BRC repeats. If a protein is important, it is most probably 
conserved throughout evolution. The structure and homology of BRC repeats were 
further studied by Bignell et al. (1997) and it was found that they were conserved in 
8 mammals including dog, swine, hamster and mice. It is of importance that the BRC 
repeats were conserved but the intervening regions were not.
1.5-3-2 Homology with c-jun transcription activation region
In a search for a similarity to proteins with known functions, BRCA2 was 
found to have a sequence similariry to the transcripton activation domain of c-jun 
(Milner et al. 1997). This region was included in exon 3 of BRCA2, aminoacids 48 to 
105, which was well conserved among mice and human indicating a functional role. 
The transcription activation role was studied by fusing this region with the DNA 
binding domain of lexA protein. The results showed a positive transcription activation 
capacity in yeast system. BRCA2 exon 3 sequences (aminoacids 18-105) also had a 
transcription activation potential in two different mammalian cell lines, namely U20S 
and NMuMG when linked to the GAL4 DNA binding domain. The minimum c-jun 
homolog}' region (residues 60-105), contributed to this activation, but the adjacent 
region (residues 18-60), have higher activation capacity alone. When assesed alone,
27
the primary activation region (residues 18-60) have a 5 fold increased activity 
compared with auxilary activation region (residues 60-105), but still lower than the 
full activation region (residues 18-105). This consequence led the authors to define 
the transcription activity of adjacent regions, and two inhibitory regions at each side 
of activation site (residues 1-18 and 105-125), which was a similar regulation of 
some transcription factors, like c-fos.
C-jun was shown to be regulated by jun-N terminal kinase (JNK), which was 
shown to bind to the BRCA2 homology region (Derijard et al. 1994). An identified 
missense mutation in exon 3 of BRCA2 (tyrosine 42 cysteine) defines a probable 
target for such kinases and tyrosine 42 might be regulating the activity of this 
transcription activation domain.
1.5-4 Mouse homologue of BRCA2
Mouse homologue of BRCA2 is very important since mouse is the most 
commonly used experimenal animal and a good model system. Connor et a l  (1997) 
described the mouse BRCA2 gene. The gene was mapped to chromosome 5 in mouse 
which was consistent with its localization to human chromosome 13. The cloning and 
the sequncing of mouse BRCA2 showed the gene to be relatively poorly conserved 
between human and mice although the size of the protein was similar (3329 amino- 
acids). There are gaps in mouse gene when compared with human homologue, 
explaining its shortness. The overall identity between two sequences was 59.2% with 
72.6 similarity. The mouse BRCA2 gene was expressed at a wide range of tissues 
with the exception of lung which could not be detected after 40 cycles of PCR 
amplification from cDNA. The highest expression was seen at testis, thymus, eye, 
ovary and mammary gland. These results demonstrate the striking smilarity of mouse
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and human BRCA2 expression as well as the similarity of BRCA2 and BRCAl
expression m mouse.
1.5-5 Expression studies and the role of BRCA2 in cell fate
In 1996, several studies were done considering the role of BRC genes in cell 
proliferation and differentiation. The lack of these genes is known to produce tumors 
especially at tissues that are highly controlled by hormones (breast, ovary and 
prostate). The hormonal induction in these tissues produce a proliferative response, 
like the mensturational increase and decrease of women’s breast size. Such alterations 
in these tissues are the result of extensive proliferation and apoptosis so it is possible 
that BRC genes have a role in cell fate. Vaughn et al. (1996) reported the first 
functional study on BRCA2 concerning its expression pattern to implicate the role of 
BRCA2 in tumor suppression. Go and Gi synchronized normal human mammary 
epithelial cells (HMECs), ovarian epithelial cells (NOSEl) and MCF-7 cells were 
used to experiment the expression pattern of BRCA2 (and BRCAl). The cells 
arrested at Go and early Gi were having low levels of BRC expression whereas when 
they were stimulated to proliferate, the expression increases reaching a maximum at 
late GI and retained throughout the S-phase. Go arrest of these cells were achieved by 
growth factor deprivation and Gi arrest of cells were achieved by the drug Lovastatin. 
When released from the Go-phase the maximum expression was detected at 9***, 12* 
and 15* hours, lagging one time interval of Histone2A (H2A) which reached 
maximum at 12* and 15* hours, indicating cells entered S-phase. This result also 
indicates that the expression of BRC genes were not coupled to bulk DNA synthesis 
like H2A. When Lovastin blocked cells were released by adding fresh medium 
containing mevanolic acid, a high BRC expression was seen after 23 hours (at the
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time when 21% of the cells were in the S-phase) and retained throughout the S-phase. 
Levels of mRNA from the estrogen inducible pS2 gene was very high through 
Lovastatin block and retained at 5*** and 23^  ^ hours, but declined at later points, 
showing an estrogen induced gene not coupling from BRCAl and BRCA2. Rajan e( 
al. (1996) clarified the expression pattern on BRCA2 by concerning differentiation 
and proliferation together. The results obtained in the case of proliferative stimulus 
were the same with the observations of Vaughn et al. (1996). The cell cycle arrested, 
transformed and non-transformed mammary epithelial cells did not express BRC 
genes, whereas the expression peaked at late Gi and S-phase upon proliferative 
stimulus. Upon induction with lactogenic hormones, BRCAl and BRCA2 expression 
was found to be steady and high although the cells were postconfluent. This data 
strongly suggested that the upregulation of BRC genes during differentiation occurred 
in a proliferation-independent manner. The parallel regulation of BRC genes 
suggested a similar control mechanism of induction of both of the genes but it is not 
true to call these genes to be redundant since the tumor incidence and tumor type 
associated with each gene are different.
These studies above indicate the BRCA2 expression pattern in cell culture, 
which is not a in vivo system so might be affected by some artifacts. Rajan et al. 
(1997) defined a controlled vivo system for studying BRCA2 expression. As the first 
part of experiment, the spatial and temporal expression pattern of the murine 
homologue of BRCA2 in fetal development, adult tissues and in mammary gland 
during postnatal development were investigated. The results indicated that BRCA2 
was expressed at very high amounts in proliferationg cellular compartments, 
particularly those undergoing differentiation. Several studies defined the expression 
pattern of BRCAl in mice (Lane et al. 1995, Marquis et al. 1995), which was
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virtually indistinguishable from that of BRCA2, although these genes confer no 
homology. This study and previous ones thus described the importance of BRCA2 
expression in proliferation and differentiation which could be similarly regulated with 
BRCAl. The only difference in expression of these two genes was identified by Rajan 
et al. (1997) at endocrine target tissues (testis and mammary gland), so the 
probability of differential control of BRC genes by sex hormones was proposed. The 
differences were significant especially in testis (during spermatogenesis) and breast 
(during preganacy).
In testis, various differentiating cell types appear during spermatogenesis, 
which occur during the first weeks of life in mice. The mRNA level in testis was 
investigated by RNase protection assay as a function of age from 6 to 27 days 
following birth. This analysis revealed a progressive increase in BRCA2 mRNA levels 
beginning at day 12 and reaching a peak by 4 weeks of age and remaining high in 
adult life. This was not the case for BRCAl, which was constantly expressed during 
the same period.
In situ hybridization was used to determine the spatial and temporal expression 
pattern of BRC genes in mammary gland during postnatal development. High levels of 
BRCA2 expression was seen in immature mice, predominantly at breast epithelium, 
with decreasing levels as the mice got matured. As assayed by RNase protection, 
BRCA2 mRNA levels in the female breast increased sharply early in pregnancy, when 
alveolar buds begin to differentiate to form, mature milk producing alveoli. During the 
rest of pregnancy, expression decreased, reaching the pre-pregnancy values at day 20. 
When BRCAl was concerned, the expression patem was similar of BRCA2, but the 
magnitude of upregulation in pregnancy and the steady state expression was at least 
two times of BRCA2.
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As the second part of the experiment, the expression of BRCAl and BRCA2 
was investigated in ovariectomized animals with external supply of 17 |3-estradiol and 
progesterone. Steady state levels of BRCAl and BRCA2 were significantly lower in 
mammary glands of overiectomized animals when compared with the normal 
littermates. When either of 17 P-estradiol or progesterone, or both was supplied to 
operated animals, there was a significant increase in BRCAl and/or BRCA2 
expression. The up-regulation of mRNA of BRCA2 was very low when compared 
with BRCAl supporting the higher incidence of BRCAl mutations in ovarian and 
mammary cancers.
These observations partially explain the gender and tissue specific cancers 
that are due to mutations in BRCAl and BRCA2. This may be the couse of difference 
in the phenotype of families with breast and ovary cancer (due to mutations in 
BRCAl) and families with male and female breast cancer (due to mutations in 
BRCA2)
1.5-6 Gene knock out studies
In vivo experiments are essential for especially functional studies. Sharan et al. 
(1997) reported the first knock-out mice model for studying the function of BRCA2. 
Mouse embryonic stem cells were targeted by a targeting vector with a selection 
marker, which was designed to delete 2.8 kb of BRCA2 genomic locus, including the 
splice acceptor site and 812 aminoacids of exon 11. The vector was electrophorated 
into embryonic stem cells and 4 of the 8 clones were injected into blastocycts. Most of 
the chimaeric mice, bom to carry the mutant BRCA2 were fertile and produced 
BRCA2 heterozygous progeny. Being a model for predisposed people, BRCA2-/+ 
mice were thought to have high risk of developing breast tumors, but none of the 
heterozygous mice developed any tumors until at least eight months of age. Six of the
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BRCA2-/+ mice intercross failed to produce any offspring, indicating the importance 
of BRCA2 for embryonic development. Such heterozygous mice carrying a 
homozygous mutant embryo were dissected at various stages of development. At 
E6.5 (embryonic day 6.5), the BRCA2 null embryo was not seem to be different than 
the normal embryos, but at E7.5 (embryonic day 7.5), 25% of the null embryo 
exhibited a mutant phenotype. At this time of development BRCA2 expression was 
detectable in normal embryos, which was coupled with the formation of mesoderm 
and migration of cells of mesodermal origin into ectoderm to form structures such as 
amnion and chorion. BRCA2 homozygous mutated mice displayed very little, if any 
mesodermal tissue and no sign of migration, although the presence of mesodermal 
tissue was confirmed by the expression of brachury gene.
The interpretation such a result was hard, since the phenotype of BRCA2 null 
mice might be due to some differentiation or proliferation defects. As the null embryo 
were functionally equivalent to those carrying no mutations at E5.5, a heterozygous 
embryonic stem cell line was targetted by another similar targetting vector at prenatal 
day 6. 12 clones were obatained, hoewever the Southern blot analysis revealed that 
none of the clones distrupted the remaining allele of BRCA2, instead, the clones had 
targetted the mutant allele. Even the presence of positive selection didn’t helped to 
isolate BRCA2 -/- cells indicating the importance of at least a single allele of BRCA2 
for survival and proliferation of ES cells. The authors also concluded for the role of 
BRCA2 in development to be in proliferation, rather than differentiation since BRCA2 
expression began at E6.5, increased to high amounts at E7.5, at the time when the 
entire embryo was undergoing its most rapid phase of cellular proliferation.
In another study done by Ludwig et al. (1997), the phenotypes of BRCAl, 
BRCA2, BRCA1/BRCA2, BRCAl/p53 and BRCA2/p53 knock out mice determined.
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BRCAl was targetted at its exon 2, which was shown to contain a ring finger motif, 
and BRCA2 was targetted at its exon 11, by insertion a stop codon. BRCAl and 
BRCA2 heterozygous mice were indistinguishable from their littermates. Similar 
results were also observed by Sharan et al. (1997). One of the BRCA2-/+ mice 
developed a squamus cell carcinoma of skin at 4 months of age, but the 
heterozygosity was defined at BRCA2 locus and the tumor had no relevancy with 
BRCA2. The results of intercrosses between BRCA2 mice and between BRCAl mice 
produced no BRCA null progeny indicating homozygous mutations in these genes 
result in embryonic lethality. For analyzing the lethal phenotypes, pregnant females 
were sacrificed at different times. A high incidence of empty decidua was observed in 
BRCAl-/+ intercrosses (about 50%), containing only giant cells and extraembryonic 
membranes. This was not the case for BRCA2-/+ intercrosses (6%) and all the 
nullizygous embryos were seen to be quite uniform especially before embryonic day
9.5 (E9.5). The histological and morhological analysis revealed that BRCAl null 
embryos were hard to develop 3 germ layers and head fold, reduced in size and the 
most advanced ones had a yolk sac with blood islands. Another feature of BRCAl 
null embryos was inconsistency, since the gross morphology of these embryos differ 
very much. In contrast to BRCAl mutants, the E9.5 BRCA2 nullizygotes were all 
similar and exhibited a reduced embryonic size with head-folds, a large allantois and 
an expanded yolk sac with visible blood. Athough, slightly reduced in size, BRCA2-/- 
embryos developed 3 germ layers at E5.5 and possessed an anteroposterior axis at 
E8.5. The developmental problems of BRCA2 nullizygotes were reduction in size, 
poor development of amnion, loose structure of mesodermal layer and lacking 
somites.
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The growth defficiency of BRCA2 knock out embryos were previously 
reported by Sharan et al. (1997) and linked to hypoproliferation although no 
experimental evidence was shown. In the study of Ludwig et al. (1997), a cell 
proliferation assay was done to qualify the growth of the nullizygotes by injetion of 5- 
Bromo-2’-deoxyuridine (BrdU) 1 hour before the sacrefice of mother. Incorporation 
of BrdU into DNA was assayed for counting the labeled and unlabeled nuclei. 
Embryos at E6.5 were found out to be no different than the normal controls whereas, 
at E7.5, the BrdU positive nuclei in normal embryos appear to be 15% higher than the 
nullizygotes. Interestingly, this was the time when BRCA2 expression became 
siginificant, so growth retardation could be related directly to hypoproliferation and 
uninduced BRCA2 expression.
To examine the combined effect of BRCAl and BRCA2 mutations, BRCAl (- 
/+) BRCA2 (-/+) double heterozygotes were crossed. Fiflhy one decidual swelling 
were reported and the mothers were dissected at E9.5. Nine of the decidua were 
empty, whereas in the remaining 42, all expected genotypes were chracterized at 
expected rates. Embryos with at least one wild-type allele of each gene were normal 
and embryos lacking only one of the gene showed the phenotypic chracteristics of 
each mutation. Two of the 42 recovered decidua contained double nullizygous 
mutants. One of these had developed an allantois and severely reduced in size whereas 
the other consited of only yolk sac and giant cells. The double nullizygotes were 
phenotypically more similar to the BRCAl null mutants.
In the study of Ludwig et al. (1997), the phenotype of p53/BRCA2 knock 
out mice was also defined. The majority of E9.5 embryos possesing either one wild 
type of each gene or lacking only p53 were normal (with 15-25 somites), although 
they were exencephalic. Of eight embryos lacking BRCA2 (all heterozygous for p53).
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two were smaller than their most advanced littermates, but otherwise normal with 15- 
20 somites (other six were abnormal with variable phenot5T>es). Two double 
nullizyguos recovered at E9.5 were similar to the most advanced BRCA2 knock-out 
littermates, except exencephaly. The investigations done at E l0.5 showed that, the 
embryos having at least one wild type allele of each gene and most of the embryos 
lacking p53 were normal (some p53 null embryos were exencephalic). There were five 
embryos lacking BRCA2 and heterozygous for p53,and they were all abnormal with 
variable phenotypes. All of the double nullizygotes (n=5), except one were more 
developed than the most advanced BRCA2-/- littermates with some exhibiting 
exencephaly. The exceptional double mutant embryo was indistinguishable from 
normal except that it also exhibited exencephaly.
Such results were also obtained in another knock-out study, which showed the 
partial restoration of embryonic lethality of MmRAD51 in p53-/- background (Lim et 
al. 1996). These results may indicate a possible antagonistic effect of p53 induced cell 
cycle arrest and BRCA2 mediated dsDNA repair. In p53 positive background BRCA2 
knock-out embryos had extensive growth retardation. This growth retardation is 
mostly due to growth arrest instead of apoptosis because increased cell death is not 
chracterized as a feature of BRCA2 knock-out mice (Sharan et al. 1997). It could be 
the case that BRCA2 null, p53 positive cells can not repair dsDNA breaks, so 
undergo p53 mediated cell cycle arrest, whereas double (p53 and BRCA2) knock out 
cells progress through the cell cycle without any control of damaged DNA. This 
definition of partial restoration of embryonic lethality in p53-/-BRCA2-/- mice system 
also explains the rare involvement of BRCA2 in sporadic breast tumors. Kinzler and 
Vogelstein (1997) defined the two different subgroups of TSGs as ‘caretakers’ and 
‘gatekeepers’. ‘Gatekeepers’ have a negative regulatory role in cell cycle progression
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and positive role in promoting cell death. Each cell type has one or a few 
‘gatekeepers’ and by the inactivation of specific ‘gatekeeper’, a very specific tissue 
distribution of cancer arises. Retinoblastoma, neurofibromatosis type I and 
adenomatous polyposis coli are well chracterized ‘gatekeepers’, leading to the specific 
tumors of retina, Schwann cells and colon. The mutations in ‘gatekeepers’ directly 
promote tumor initiation, since the control of cell cycle progression and cell death was 
diminished.This is the opposite for ‘caretakers’, since they have role in maintaining the 
integrity of the genome. If a ‘caretaker’ has loses its function, it promotes an increase 
in the mutation rate, so the second hit at a ‘gatekeeper’ is more probable. Secondary 
mutations are essential for neoplastic transformation. Known caretakers include 
mismatch and nucleotide excision repair genes. The definition of BRCA2 null cells to 
be vulnerable to DNA demage and a possible interaction of BRCA2 with a known 
dsDNA break repair gene (Sharan et al. 1997) promotes the idea that BRCA2 is a 
‘careteaker’, rather than a ‘gatekeeper’.
1.5-7 Protein-protein interactions and functional studies
BRCAl protein was shown to interact with HsRadSl, a protein likely to be 
involved in the repair of double-strand DNA breaks (Scully et al. 1997). For 
identifying the proteins interacting with MmRadSl, Sharan et al. (1997) performed a 
yeast two hybrid screen with a T-cell complementary DNA library. A C-terminal 
region of mouse BRCA2, coding for the amonoacids 3138-3232 was isolated. The 
results were confirmed in mammalian cell culture and the association appeared to be 
much stronger with MmRadS 1 as the prey and BRCA2 as the bait. This result lead the 
proposal of self transcriptional activity of the specific region of BRCA2, but it was 
shown to be not the case since without MmRadSl, DNA binding domain fused
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BRCA2 (residuesS 138-3232) had no transcription activation. This region was studied 
by Milner et al. (1997) and shown to produce no transcription activator activity alone. 
Sharan SK. et al. (1997) also performed a deletion analysis on BRCA2 as the bait, 
for determining the crucial aminoacids for interaction. The minimal region allowing a 
strong association with MmRadSl was turned out to be a 36 aminoacid fragment 
(residues 3196-3232). Deleting 13 aminoacids (3213-3226) of this fragment 
destroyed all the interaction. The 36 and 13 amino acids were 95% and 100% 
conserved between mouse and human suggesting an critical role. The same kind of 
deletion analysis performed on MmRadSl revealed the first 43 aminoacids to be 
critical for BRCA2-MmRad51 interaction.
Bacterial RecA protein is known to have role in homologous recombination 
and the generation of Holliday junctions. This protein has high affinity for binding 
single strand DNA (ssDNA). When it binds to ssDNA its affinity to double strand 
DNA increases and both ssDNA and dsDNA are accomodated in a 100 angstrom 
groove of the protein. The protein walks on the DNA, and reaching a homologous 
site, ATP catalyzed strand exchange begins (Alberts et al. 1994). Genetic 
recombination is essential to produce the genetic diversity and to repair DNA upon 
exposure to mutagens producing single strand and double strand DNA breaks. The 
murine homologue of bacterial recA protein (MmRADSl) was known to have 
functions like binding to single strand and double strand DNA and ATP catalyzed 
strand exchange (Radding et al. 1991 and Sung et al. 1994). Although, yeast 
mutated for RAD51 was shown to survive without double strand break repair and 
meiotic recombination (Shinohara et al. 1992), murine mutants of this gene are not 
viable (Lim et al. 1996). The hypersensitivity of MmRADSl mutants to y-radiation 
was also defined by Lim et al. (1996). Such a phenotype is expected in BRCA2
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knock-out mice if MmRAD51-BRCA2 interaction is significant. Sharan et al. (1997) 
investigated the radiation sensetivity of BRCA2 null mice embryos at E3.5, since 
BRCA2 knock-out mice can not develop fially. Embryos were obtained from BRCA2- 
/+ intercrrosses and grown in vitro for seven days. The inner cell mass and the number 
of trophoblasts were assayed with exposure to 400 Rads of y-radiation. Inner cell 
mass was marginally reduced in negative controls, but totally ablated in eight of the 
eight BRCA2-/- embryos. When the number of trophoblasts were concerned there 
was only a slight decrease in irradiated controls (average=31, n=8) when compared 
with non-irradiated ones (average=35, n=13). However in the case of the irradiated 
BRCA2 null embryos (n=8), the average number of trophoblasts were 15. The 
embryonic lethality, and sensitivity to y-irrdiation proposes an interaction of BRCA2 
andRADSl.
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2 -AIM and STRATEGY
BRCA2 is an important gene whose germline mutations predispose to breast 
cancer. Most of the BRCA2 mutations give rise to truncated proteins lacking the C- 
terminal end of the protein. Although there is no clear evidence for the function of 
BRCA2, it was shown to interact with mammalian homologue of bacterial RecA 
protein which is involved in repair of DNA strand breaks and homologous 
recombination. Such large proteins may have multiple Sanctions like being a 
matchmaker, transcription activator or functions concerning cell fate. For fully 
understanding the specific cellular functions of BRCA2, it is necessary to develop 
biochemical tools such as recombinant protein fragments and monoclonal antibodies 
directed against different regions of this large protein.
For this reason we decided to express human BRCA2 protein fragments in E. 
coli. and purify them in large quantities As a first step the extereme C-terminal 
portion of BRCA2 (E7) is expressed and purified.
First of all, we wanted the fragments to be modular and could be expressed 
either one by one or as combined proteins. This was achieved by identification of 
restriction enzymes that cut BRCA2 only once. Considering the fidelity and the 
capacity of PCR reaction, we divided BRCA2 (10485 bp) into 7 overlapping 
fragments which contain two single cutter sites, one at its 5 prime (5’) and the other 
at its 3 prime (3’) end. The fragments and the single cutters are defined in figure 5. 
Genomic DNA was an available source so, first the fragments corresponding the exon 
11 (E2 and E3) were PCR amplified. The 3 prime (3’) region of the gene was also
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considered to be important since most of the mutations in BRCA2 are ffameshift 
mutations leading to premature truncation of translation. With the available cDNA, 
E6 and E7 were also amplified to correspond to the exon 19 to exon 27, stop codon.
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Figure 6: The PCR fragments of the BRCA2 gene; The fragments 
that were used for the cloning experiments are shown below the exon 
structure of BRCA2 gene with names of restriction endonucleases.
The forward primers were designed to contain a BamHI site and reverse 
primers were designed to contain a Hindlll site. Pfu amplified blunt end PCR 
fragments were cloned into PCR-Script SK+ AMP cloning vector and then subcloned 
into pQE expression vector in correct frame. The advantages of the pQE vector are 
the high expression and easy purification of expressed proteins by the help of a 6XHis 
tag attached either the carboxyl or the amino terminus. 6XHis tag is a very uncommon 
protein motif in prokaryotes and it has a high affinity to bind Ni-NTA agarose 
columns. After binding to the column, 6XHis tag carrying proteins can be easily 
removed by antagonizing with imidazole (250 mM).
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E7 was a trial for checking the feasibility of bacterial expression and 
purification of BRCA2 encoded proteins. The other domains of the protein will be 
cloned and expressed for defining the structural and functional aspects of BRCA2.
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3- MATERIALS METHODS
Table-6: Primers used in this study.
Synthetic oligonucleotide primers used in this study
Name Sequence 5’- ->3’
Location
Strand position Size
Tm
OC
BRCA2F2 gggATCCACTTCTgAggAATgCAgA sense 3691 25 61
BRCA2R2 gAAgCTTggCAgCTgTgATCTCAATgg antisense 4992 27 65
BRCA2F3 CggATCCCAgTTggTACTggAAATC sense 4708 25 61
BRCA2R3 CAAgCTTCAATACTggCTCAATACC antisense 5548 25 55
BRCA2F6 AggATCCTCTgCCCTTATCATCgC sense 8630 24 61
BRCA2R6 CAAgCTTCgTATTTggTgCCACAAC antisense 10160 25 61
BRCA2F7 AggATCCAgAATCCAAATCAggCCTTC sense 9614 27 63
BRCA2R7 AagCTTgTCgCCTTTgCAAATgCTTAg antisense 10450 27 63
3.1 PCR
Polymerase chain reaction had been used during this study in order to amplify 
the human BRCA2 gene fragments. The requirements for PCR are listed below 
(Saiki et al. 1988). Pfu DNA polymerase was used to catalyze the reaction because 
Pfu DNA polymerase exhibits the lowest error rate of any thermostable DNA 
polymerase (1.3 x 10-^ ) and the buffer conditions were described by the supplier.
1-Template DNA with known flanking sequences
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2- OligonucIeotides with homologous sequences to that of the template 
flanking region (primers)
3- DNA polymerase and appropriate buffer
4- Deoxy-nucleotide triphosphates
5- Temperature cycling machine
A standard 100 \xl reaction set up in a 0.2 ml PCR tube
primers 0.1-1 jiM of each primer (reverse and forward) 
dNTP 0.2 mM diluted from the 10 mM stock
buffer IX diluted from the lOX stock
template 10 ng of genomic or plasmid DNA 
Made up to 100 (x/ with MilliQ water 
enzyme 2.5 unit of Pfu DNA polymerase
Each reagent and tube were placed on ice. To perform a hot-start PCR the 
thermal cycler was preheated to approximately 90®C before placing the tubes into it.
3.2 Purification of PCR products
PCR products were purified by precipitating the DNA with ammonium 
acetate. 1/10 volume of lOX STE buffer, equal volume of 4M ammonium acetate and
2.5 volume of 100% (v/v) ethanol were added to the PCR products sequentially. The 
reaction tube was centrifugated at 13000 rpm for 20 minutes at room temperature to 
pellet DNA. The supernatant was removed carefully and discarded. The pellet was 
washed with 200 |xl of 70% (v/v) ice-cold ethanol and dried. DNA was resuspended 
by using TE buffer.
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3.3 Horizantal electrophoresis of DNA
Agarose,which is extracted from seeweed is a linear polymer. Charged molecules 
like DNA or RNA became oriented in an electric field and migrate towards the 
attracting pole of the field. Such charged polymeric molecules are also capable to 
migrate within the porous structure of a linear polymer, like agarose. These properties 
of DNA and RNA were abused to qualitatively and quantitatively analyze nucleic 
acids. In the presence of a good electrolitic buffer and a electric field, nucleic acids 
migrate towords cathode through the linear pores of polymerized agarose. The 
seperation capacity of such gels depend on the agarose content which is summarized 
in table 7.
TabIe-7: The agarose content and the seperation range of DNA
Amount of agarose in the gel Efficient range of
(%w/v) seperation of DNA (kb)
0.3 5-60
0.6 1-20
0.7 0.8-10
0.9 0.5-7
1.2 0.4-6
1.5 0.2-3
2.0 0.1-2
45
Generally ТАЕ and ТВЕ buffers were used to define a conductive medium. 
These buffers have their best electrolytic ability when used as 0.5-IX solutions. The 
contents of these buffers are summarized in table 8.
TabIe-8: TAE and TBE buffers
Buffer Working solution Concentrated stock solution 
( liter)
SOX: 242 g Tris base
Tris-acetate IX: 0.04M Tris acetate 57.1 ml Glial acetic acid
(TAE) O.OOIMEDTA 100m lof0.5M ED TA
5X: 54 g Tris base
Tris-borate (TBE) 0.5X: 0.045M Tris borate 27.5 g boric acid
O.OOIMEDTA 20 ml of 0.5 M EDTA
Agarose is added at desired amount of 0.5-IX of electrophoresis buffer 
(volume adjusted vsdth dH20) and the slurry mixture is heated until it gets transparent. 
The gel aparatus must be set before and the wells that DNA will be inserted must be 
defined with combs that were provided with the gel aparatus. After pouring and 
solidification, the gel is ready to be placed in a tank filled with the same running buffer 
and ready for DNA to be inserted to the holes provided by the comb. A steady 
voltage of 50-100V is applied to the buffer and the tank is frequently checked for 
overheating. It is of importance to consider the place of holes in the gel and the 
direction of the voltage since DNA will run from - to +.
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Visualization of DNA in the gels could be achieved by soaking the gel in 
ethidium bromide solution (10 (g/ml) and staining for 10 minutes. The DNA could be 
viewed under UV light.
3.4 DNA ligation
DNA fragments, cut from agarose gel and recovered by Promega Wizard PCR 
Prep-kit were used for ligation. For directional cloning (where both vector and insert 
DNA has protruding ends) approximately 1:4 ratio of vector and insert DNA was 
mixed with the T4 DNA ligase buffer and 1 to 3 units of T4 DNA ligase. The reaction 
is carried out either 2 hours at room temperature or 16 hours at 12°C. For blunt end 
ligation, insert:vector ratio could be increased up to 40 and preferably the reactions 
are accomplished at 12°C. The reaction could be stopped directly by heating at 65®C 
for 10 minutes or directly used to transform competent bacterial cells.
3.5 Bacterial strains, media and storage 
Table-9: E. coli strains used in this study.
Strains of E.coli:
Strain Genotype Usage Source
DH5a F; <l)80d/acZAM15, Host for Hanahan
( A/acZYA-argF)U169, recombinant (1983)
recA\, endAXhsdSAl (rk‘, mk^). plasmid
«//?E44, X, thi-\, gyrJK, relA\
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Strain Genotype Usage Source
M l5 (pREP4) Nal Str rif ^  lac'. Host for Villajero and
ara ", got/ ■, mil ' , F ’, expression Zabin
uvr rec A  ^ studies (1974)
Strain Genotype Usage Source
JM 109 F’, lac**, traD35 A {lac Z)m\S Propogation Stratagene
proAQ!recA\ e l4" of the
endAX gyrA96 {Naf) thi vector pQE
hsdR17 supEAA
(mcrA~) relAlA {lac-proAS)
Strain Genotype Usage Source
Epicuran Coli A (/wcrA)183 A(/wcrCB- Host for Stratagene
XL-lBlue MRF’ Zi5i/SMR-/wrr)173 endAX, recombinant #200248
Supercompetent supEAA thi-1 recAl, plasmid
cells gyrA96, relAX, /ac{F’proAB
lac\\ Z(M15 Tn5 (Kan·)}
Solid and liquid mediums :
LB medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl.
LA medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl and 1% agar.
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Supplemented with appropriate antibiotics. 
Antibiotics
Ampicilin and kanamycin were used in this study.
Table-10: Stock and working solutions of antibiotics.
Stock solution working concentration
name of 
the
antibiotic
concentration storage stringent
plasmids
relaxed
plasmids
Ampicilin 50 mg/ml in H2O - 200c 20 |ig/ml 60 |ig/ml
Kanamycin 10 mg/ml in H2O - 200c 10 pg/ml 50 pg/ml
3.6 Storage of E.coli strains and plasmid harboring bacteria
Strains oiE.coli were stored in glycerol (long term storage). Glycerol cultures 
of E.coli were prepared by adding 0.81 ml of fresh culture to 0.91 ml of sterile 80% 
glycerol in a sterile screw capped tube. The tubes were vortexed until homogenous
and were then frozen and stored at -lO^C.
3.7 Preparation of competent cells
Cells were made competent using a modification of the CaClj method 
described by Maniatis et a i, 1982.
5 ml LB was inoculated using a single colony from a freshly grown plate of 
the E. coli strain to be used, and was incubated for approximately 2 hours, until the 
culture was slightly turbid. The culture was then cooled on ice for 5 minutes, 1 ml
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aliquots were added to microcentrifiige tubes and then the cells were pelleted by 
centrifugation (1 minute at 13,000 rpm ). The cells were resuspended in 0.5 ml of 50 
mM CaClj by gentle vortexing, before being placed on ice for 30 minutes. The cells 
were pelleted by centrifiigation (1 minute at 13,000 rpm ) and the supernatant was 
discarded. The pellet was resuspended in 0.1 ml of CaClj with gentle vortexing. The 
cells were then stored on ice until required for transformation. Alternatively
competent cells were prepared and stored at -70OC until required. 500 ml of LB was 
seeded with a 10 ml of overnight culture and grown to an 0.6. Cells were
harvested by centrifugation at 5000 rpm for 10 minutes at 4®C, before being 
incubated on ice for 20 minutes. The cells were harvested as before, resuspended in 
25 ml of 50 mM CaClj /20% glycerol and aliquoted into microcentrifuge tubes before
being frozen. Samples were stored at -TO^C and were viable for at least 2 months. 
Cells were thawed on ice prior to the addition of DNA.
50 mM CaClj
0.735 g CaClj .2H2O 
Add H2O to 100 ml
Filter sterilized using a disposable filter, or autoclaved
3.8 Transformation of bacterial cells
The DNA to be transformed (usually half of the ligation mixture or 
approximately 100 ng of plasmid DNA) was added to the 100 \x,l of competent cells, 
mixed gently and incubated on ice for 30 minutes. The cells were then heat-shocked
at 42®C for 90 seconds and chilled by placing on ice for 2 minutes. 1 ml of 
prewanned LB was then added and the suspension was incubated at 37®C for 1 hour.
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Each sample was pelleted by centrifugation at 13,000 rpm for 2 minutes, resuspended 
in 100-200 yd of LB and plated onto selective medium and incubated overnight at 
37®C to allow the growth of the transfomants.
If the vector-host system used featured a-complementation of P-galactosidase 
to enable for blue/white selection of recombinants, then 25 \il of a 20 mg/ml stock 
solution of X-Gal (5-Bromo-4-chloro-3-indolyl-|3-D-galactoside) in dimethyl 
formamide and 20 p/ of a 20 mg/ml stock solution of IPTG (Isopropylthio-P-o- 
galactoside) in dHjO were added to the agar plates 1 hour prior to the spreading the
cells. If the host was DHSoMCR then IPTG was omitted, since this strain lacks the 
lac repressor and hence expression from Plac promoter is constitutive.
3.9 Small scale preperation of plasmid DNA (Mini-preparation)
This protocol is based on the alkaline lysis method of Bimboim and Doly
(1979).
The transformed bacterial strain containing the plasmid of interest was grown
at 37®C overnight in 5 ml of LB+antibiotic. 1.5 ml of the bacterial culture was 
pelleted by centrifugation for 1 minute (bench-top microfuge, 13,000 rpm) in a 1.5 
ml mictofiige tube. After the discartion of the supernatant, the cells were resuspended 
in 0.1 ml of ice-cold solution I and stored for 5 minutes at room temperature. 0.2 ml 
of solution II was mixed by inversion, the tube was then stored on ice for 5 minutes. 
Bacterial chromosomal DNA and proteins were precipitated by the addition of 0.15 
ml of ice-cold solution III. The mixture was left on ice for 5 minutes, then 
centrifugated in a bench-top centrifuge for 5 minutes to pellet the host DNA and 
proteins. The supernatant was mixed with an equal volume of phenol-chloroform
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(1:1) and centrifugated in a bench-top microflige for 3 minutes to seperate the two 
phases. The top phase was removed and plasmid DNA precipitated by mixing it with
2.5 volumes of 95% ethanol, and pelleted by centrifugation for 10 minutes (bench-top
microfuge, 13,000 rpm) after keeping the mixture at 4°C for 15 minutes. The 
supernatant was discarded and the pellet was left for 15-20 minutes at room 
temperature to dry and then resuspended in 20-30 \il of TE buffer containing 10 pg/ 
ml RNase A. Samples were stored at 4®C.
This procedure yields approximately 3 pg of DNA.
Solution 1
50 mM glucose
25 mM Tris Cl (pH 8.0) 
lOmMEDTA (pH 8.0)
Solution I can be prepared in batches of approximately 100 ml, autoclaved for 
15 minutes at 10 Ib/sq. in. on liquid cycle, and stored at 4®C.
Solution n
0.2 NaOH (fi’eshly diluted from ION stock)
1% SDS 
Solution m
5 M potassium acetate 60 ml 
glacial acetic acid 11.5 ml
HjO 28.5 ml
The resulting solution is 3 M with respect to potassium and 5 M with respect
to acetate.
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зл о  Restriction enzyme digestion of DNA
DNA restriction reactions were carried out in a total volume of 20-100 |il with
5-10 units of restriction enzyme. 1 ц1 of boiled Rnase A (Img/ml) was used where 
appropriate. The volume of the reaction buffers were arranged to be IX and the 
enzyme volume was never greater than 1/1O**“ of the reaction volume so as to prevent 
star activity due to the high glycerol concentration.
ЗЛ1 Midiprep of plasmid preparation
Midi-preparations were carried out by using the kit supplied by Promega 
(Catalog number: A7510)
ЗЛ2 Maxiprep of plasmid preparation
Preparation of large scale bacterial culture
The bacterial strain containing the plasmid of interest is first grown in a 30 
ml culture with necessery antibiotic until late log phase (ODeoo of 0.6) then inoculted 
in 500 ml LB or Terrific Browth medium for 10-12 hours (2.5 ml of a solution of 
chloramphenicol (34 mg/ml in ethanol) could be added when ODeoo of 0.4 is reached 
so as to increase the yield from low copy number plasmids.). The cells are harvested 
by centrifugation at 4000 rpm for 15 minutes at 4°C in a Sorvall GS3 rotor (or 
equivalent). The supernatant will be discarded and allow to drain away in a upside 
down position. Resuspend the cells in 100 ml of ice cold STE.
STE :
0.1 MNaCl
10 mM Tris Cl (pH:8.0)
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1 mMEDTA(pH:8.0)
Collect the cells again by centrifugation like described above.
Lysis by Alkali
This protocol is based on the alkaline lysis method of Bimboim and Doly 
(1979) and the solutions were described above in the miniprep preparation of plasmid 
section.
The bacterial pellet is resuspend and washed in 18 ml solution I (in the 
presence of chloramphenicol, resuspend in 10 ml and follow the instructions in 
parentheses).
2 ml (1 ml) of freshly prepared solution of lysozyme is added (10 mg/ml in 10 
mM Tris Cl (pH:8.0).
40 ml (20 ml) of freshly prepared solution II is added, the top of centrifuge 
tube is closed and the bottle is inversed several times. The bottle must be stored at 
room temperature for 5-10 minutes.
20 ml (15 ml) of ice cold solution III is added, the top of the bottle is closed 
and shaked several times. The bottle must be stored on ice for 10 minutes.
The cell lysate iscentrifuged at 4000 rpm for 15 minutes at 4°C. The rotor 
must stop without braking.
The suprenatant is filtered through 4 layers of cheesecloth into a 250 ml 
centrifuge bottle. Adding 0.6 volume of isopropanol and mixing well, the nucleic 
acids are ready to precipitate. The bottle must be store at room temperature for 10 
minutes.
Nucleic acids are recovered by centrifugation at 5000 rpm for 15 minutes at 
room temperature in a Sorvall GS3 rotor (or equivalent). Salt may precipitate if the 
centrifugation is performed at 4°C. The supemantant is poured off gently and the
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bottle is inverted so as to allow all fluid to drain away. The pellet and the walls of the 
bottle is washed with 70% ethanol at room temperature. After draining off ethanol, 
by the help of a pasteur pipette attached to vacuum, remove any beads of liquid 
attached to the walls of the bottle. The unaccesable ethanol is left to evaporate at 
room temperature. The pellet is dissolved in 3 ml of TE (pH 8.0) and ready for 
centrifugation in CsCl-ethidium bromide gradients.
Purification of closed circular DNA bv equilibrium centrifugation in 
CsCI-ethidium bromide gradients
The volume of the DNA solution must be measured exactly and for every mililiter, 
1 g of solid CsCl must be added to the solution. It is feasable to warm the solution to 
30°C to allow easy dissolution of the salt. The mixture is centrifuged at 8000 rpm for 
5 minutes so as to separate the proteins complexed with ethidium brromide and pure 
nucleic acids. The clear red solution at lower phase contains nucleic acids and must be 
transfered to a Beckman Quick seal tube or equivalent. For this process, a disposable 
syringe could be used. It is very important to seal the centrifuge tube correctly and not 
to overload the tube. The density gradients are centrifuged at 80 000 rpm for 16 hours 
at 20°C. Two bands appear after centrifugation in the center of the gradient and 
upper band contains the linear bacterial chromosome and nicked plasmid DNA, 
whereas the lower and thicker band corresponds to the circular plasmid DNA. The 
deep red pellet on the bottom of the tube consists of ethidium bromide-RNA 
complexes. For collection of DNA bands, first a 21-gauge hypodermic needle is 
inserted into the top of the tube to allow air to enter. For minimizing the possibility of 
contamination, first the upper band is collected. The surface of the tube is cleaned
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with ethanol and a piece of Scotch Tape is attached to the outside of the tube. An 18- 
gauge hypodermic needle is inserted just below the upper band and the upper band is 
collected. As collection is finished, the needle is plugged and a second needle is 
inserted just below the lower band of DNA and the viscous solution is collected. The 
ethidium bromide must be removed from the DNA solution by extracting at least 6 
times an equal volume of isoamyl alcohol. The DNA must also be cleared away from 
CsCl so the final solution of DNA is diluted with 3 volumes of water and 2 volumes 
of ethanol (total volume is 6X of the original) and precipitaed by centrifugation at 
lOOOOg for 15 minutes at 4°C. This method yields l-5mg of plasmid DNA.
3.13 Quantifîcation of double strand DNA
The amount of DNA in samples were determined by by reading the 
absorbance of the samples at 260 nm. An OD260 of 1 corresponds to a concentration
of 50 цg/ml for double stranded DNA, 40 |ig/ml for single stranded DNA and 20 
ljg/ml for oligonucleotides.
3.14 Expression studies and induction of bacteria
Freshly transformed bacteria harboring the expression plasmid were 
inoculated from a single colony from LB agar plate to 5-10 ml LB medium with 
selective antibiotics. The bacteria were allowed to grow to reach a OD. of 0.7-0.9 
then seperated into two tubes, one being the uninduced control. IPTG is added to be 
0.4-2.0 mM in the final concentration to one of the tubes and inoculation proceeds for 
another 5 hours.
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3.15 Purification of recombinant protein
Protein purification is done under denaturing and non-denaturing 
conditions.
3.15- 1 Small scale protein purification under denaturing conditions ;
Bacteria harboring expression plasmid was cultured overnight in 5-10 ml 
LB with adequate sellection of antibiotic. The concentration of antibiotic could be 
inreased so as to minimize the plasmid loss. Inducution of the cells were done with 
0.4-2 mM IPTG for 5 hours. Cells were harvested by centrifugation at 20000 rpm for 
2 minutes. The cell pellet was dissolved in 2 ml of buffer B.
Buffer A :
8 M Urea
300 mM NaCl
50mMNaH2PO4
Buffer B : same as buffer A but the overall pH of this buffer is adjusted to 8.0 
with HCl.
The suspension was vortexed so as to lyse the cells avoiding frothing. The 
suspension gets clear when lysis is complete. The sample must be qickly loaded to the 
column prepared and equilibrated before.
3.15- 2 Preparation and equilibaration of the column
The colunm can be prepared from a 10 ml syringe. The opening of the 
syringe was plugged with cotton glass and wetted with dH20. 200-400 p.1 50% Ni- 
NTA agarose was placed into the colunm. It is very important not to plug very much 
glass cotton that could prevent flow of the fluids by gravitational force. After allowing 
the Ni-NTA agarose to settle, 2 ml of buffer B is added and allowed to flow by
gravity. It is very important not to allow the column dry, so as the flow ends, 200 |il 
of buffer B is placed into column and the opening of the column is plugged. The 
column must equilibrate in this position for 30 min. at room temperature before 
loading.
3.15-3 Loading and purification of the sample
100 pi aliquot is taken from total lysate (fraction 1) and kept at -20°C for 
SDS-PAGE analysis of proteins. The rest of the toyal lysate is loaded on the pre­
equilibrated column. The fluid must flow by gravity. 6XHis tagged proteins were 
supposed to bind the column and the rest of the proteins were supposed to flow down 
and produce the second fraction namely; flowthrough. Washing the column 3 times 
with 2 ml of buffer C is essential to remove any unspecific bound proteins from the 
column.
Buffer C : Same as buffer A but pH adjusted to 6.3 with HCl.
These elutions are called fractions 3,4 and 5. Finally the 6XHis tagged proteins were 
removed from the column by 1 ml of buffer D (fraction 6).
Buffer D : Same as buffer C but 400 mM imidazole is added.
If wanted all the proteins that bind the column could be eluted with strip buffer 
(fraction 7), which removes the Ni^  ^ ions from the column so the proteins bound the 
ions. It is of imporance that the stripped columns can not be used again.
Strip buffer : 0.1-0.5 M EDTA pH : 8.0 
The fractions can be analyzed by SDS-PAGE protein electrophoresis.
3.15-4 Large scale protein purification under non-denaturing conditions 
100 |il of bacteria which had been inoculated from a colony on agar plate 
harboring the expression vector was inoculated into 20 ml of LB media including the
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appropriate antibiotic and incubated overnight at 37°C. 10 ml of this culture was then 
used to inoculate 500 ml of fresh LB media+antibiotic. Bacteria were grown until the 
absorbtion at 600 nm reach 0.7-0.9. IPTG is added to a final concentration of 2 mM 
and incubation was further continued for 5 hours.
Cells were harvested by spinning at 5000 rpm for 10 minutes at 4®C using a 
Sorvall GS3 rotor (or equivalent), supernatant was discarded. The pellet was 
resuspended in 5-volumes of solubilization buffer and homogenized in the 
homogenizer for 5 times of 90 second periods. It is very imprtant to keep the samples 
on ice between each homogenization to aviod protein degredation. Samples were left 
on a rotative shaker in a refiigerated room for 20 minutes. An aliquot of 0.5 ml was 
taken, and soluble and insoluble fractions were seperated by centrifugation at 15,000
rpm for 5 minutes at 4®C. Both fractions were kept at -70^C. The remaining
suspension was treated with liquid nitrogen and 37®C iteratively (freeze-thaw) 5 
times. An aliquot of 0.5 ml was taken, and soluble and insoluble fractions were
seperated by centrifugation at 15,000 rpm for 5 minutes at 4®C. Both fractions were
kept at -70°C. The remaining suspension was sonicated in ice cold water for 2 
minutes. An aliquot of 0.5 ml was taken, and soluble and insoluble fractions were
seperated by centrifugation at 15,000 rpm for 5 minutes at 4^С. Both fractions were 
kept at -70®C. The remaining suspension was centrifugated at 4®C for 10 minutes at 
13,000 rpm. The supernatant and the pellet was freezed at -70^С.
59
50 mM Sodium phosphate (NaH2P04 ) pH;8
300 mM Sodium Chloride (NaCl)
Img/ml lysozyme (freshly added)
Preparation of the column was described above in ‘small scale purification of 
proteins under denaturing conditions’ section, but since this is a large scale 
purification, 1 ml of 50% Ni-NTA agarose is placed in the column and equilibrated 
with 2 ml of buffer A.
3.15-5 Loading and purification of the sample
2.5 ml of supernatant from the supernatant was applied to the column and 
allowed to flow with gravity. This fraction was flowthrough and the 6XHis tagged 
proteins were supposed to bind the column. The column was washed 2 times with 
buffer A and 1 times with buffer B. The wash steps producing fractions W l, W2 and 
W3 supposed to clear all the non-specific bindings, whereas the 6XHis tagged 
proteins were supposed to retain. The elution of tagged proteins were done in 2 steps, 
eluting with 300 pi of buffer C and 300 pi of buffer D. The fractions obtained as total 
lysate, flowthrough, W l, W2, W3 and buffer C and buffer D could be run in a SDS- 
PAGE gel and stained with coomassie blue.
Solubilization Buffer
Buffer A
50 mM Sodium phosphate (NaH2P04) pH: 8
300 mM Sodium Chloride (NaCl)
Buffer B
Buffer A with 20mM imidazole
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Buffer C
Buffer A with 250mM imidazole 
Buffer D
Buffer A with 500mM imidazole
3.16 Analysis of proteins by SDS-PAGE electrophoresis
The glass plates were assembled according to the manufacturer's instructions 
(BioRad). The volume of the gel mold was determined according to the information 
provided by the manufacturer (BioRad). In an Erlenmeyer flask, the appropriate 
volume of solution containing the desired concentration of acrylamide for the 
resolving gel was prepared. Without delay, the mixture was swirled rapidly and the 
acrylamide solution was poured into the gap between the glass plates. Sufficient 
space (the length of the teeth of the comb plus 1 cm.) for the stacking gel was left. 
The acrylamide solution was overlayed by using a pasteur pipette with 0.1 % SDS 
(for gels containing <8% acrylamide) or isobutanol (for gels containing >10% 
acrylamide). The gel was placed in a vertical position at room temperature. After 
polymerization was complete, the overlay was poured off and the top of the gel was 
washed several times with deionised water to remove any unpolymerized acrylamide. 
As much fluid as possible was drained from the top of the gel and then any remaining 
water was removed with the edge of a paper towel.
Stacking gel was prepared in a disposable plastic tube at an appropriate 
volume and at desired acrylamide concentration. Without delay, the mixture was 
swirled rapidly and the stacking gel solution was poured directly onto the surface of 
the polymerized resolving gel. The comb was immediately inserted into the stacking 
gel, being careful to avoid trapping air bubbles. The gel was placed in a vertical
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to be loaded were prepared by heating them to lOO^C for 3 minutes in IX SDS gel­
loading buffer to denaturate the proteins. After polymerization was complete, the 
comb was removed carefully. By using a squirt bottle, the wells were washed with 
deionized water to remove any unpolymerized acrylamide.
The gel was mounted in the electrophoresis apparatus. Tris-glycine 
electrophoresis buffer was added to the top and bottom reservoirs. The bubbles that 
were trapped at the bottom of the gel between the glass plates were removed by a 
bent hypodermic needle attached to a syringe. 100-200 pg of protein was loaded in a 
predetermined order into the wells. The electrophoresis apparatus was attached to an 
electric power supply and the gel was run at a voltage that is approximately 8V/cm, 
After the dye front has moved to the resolving gel, the voltage was increased to 15 
V/cm, until the bromophenol blue reaches the bottom of the resolving gel. Then the 
power supply was turned off
The glass plates were removed from the electrophoresis apparatus and placed 
on a paper towel. By using a spatula, the plates were pried apart. Orientation of the 
gel was marked by cutting a comer from the bottom. The effective range of 
seperation of SDS-PAGE gels are illustrated in table 11 and the contents of the 
mnning and stacking gels are illustrated in tables 12 and 13.
position at room temperature. While the stacking gel was polymerizing, the samples
6 2
Table-11: Effective range o f separation o f SDS-PAGE gels.
Acrylamide concentration (%) Linear range of separation (kD)
15 12-43
10 16-68
7.5 36-94
5.0 57-212
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IX SDS gel-loading buffer
50 mM Trie Cl (pH 6.8) 
lOOmM dithiothreitol (DTT)
2% SDS (electrophoresis grade)
0.1% bromophenol blue 
10% glycerol
IX SDS gel-loading buffer lacking DTT can be stored at room temperature. 
DTT should be added, just prior to use, from 1 M stock.
Tris-glycine electrophoresis buffer
25 mM Tris
250 mM glycine (electrophoresis grade) 
0.1% SDS
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Table 12: Solution for preparing resolving gels in Tris-glycine SDS-PAGE.
Solution
components
Component Volumes (ml)
8% 5 ml 10 ml 15 ml 20 ml 25 ml 30 ml 40 ml 50 ml
CIH2O 2.3 4.6 6.9 9.3 11.5 13.9 18.5 23.2
30% mix 1.3 2.7 4.0 5.3 6.7 8.0 10.7 13.3
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.003 0.006 0.009 0.012 0.015 0.018 0.024 0.030
10%
dH20 1.9 4.0 5.9 7.9 9.9 11.9 15.9 19.8
30% mix 1.7 3.3 5.0 6.7 8.3 10.0 13.3 16.7
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
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12%
dH20 1.6 3.3 4.9 6.6 8.2 9.9 13.2 16.5
30% mix 2.0 4.0 6.0 8.0 10.0 12.0 16.0 20.0
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
15%
dHjO 1.1 2.3 3.4 4.6 5.7 6.9 9.2 11.5
30% mix 2.5 5.0 7.5 10.0 12.5 15.0 20.0 25.0
1.5 M Tris 
(pH 8.8)
1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
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Table 13: Solution for preparing 5% stacking gels
Solution
components
Component Volumes (ml)
5% gel 1 ml 2 ml 3 ml 4 ml 5 ml 6 ml 8 ml 10 ml
dH20 0.68 1.4 2.1 2,7 3.4 4.1 5.5 6.8
30% mix 0.17 0.33 0.50 0.67 0.83 1.0 1.3 1.7
1.0 M Tris 
(pH 6.8)
0.13 0,25 0.38 0.50 0.63 0.75 1.0 1.25
10% SDS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1
10% APS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1
TEMED 0.001 0.002 0.003 0.004 0.005 0.006 0.008 0.01
30% mix (Acrylamide and bis-acrylamide solution)
A stock solution of 29% (w/v) acrylamide and 1% (w/v) bis-acrylamide.
Solution was stored in dark bottles at 4®C.
10% SDS
A 10% (w/v) stock solution was prepared in deionized water 
APS
A small amount of 10% stock solution was prepared in deionized water and 
stored at A^C.
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3.17 Stalling of proteins with Coomassie bine
Polypeptides separated by SDS-polyacrylamide gels were fixed with methanol:glacial 
acetic acid and stained with Coomassie Brilliant Blue R250.
0.25 g of Coomassie Brilliant Blue R250 was dissolved in 90 ml of 
methanol:H20 (1:1 v/v) and 10 ml of glacial acetic acid. In order to remove any
particulate material, the solution was filtered through a Whatman No. 1 filter. The gel 
was immersed in at least 5 volumes of staining solution and was placed on a slowly 
rotating platform for a minimum of 4 hours at room temperature.
At the end of staining, the stain was removed and saved for future use. The 
gel was destained by soaking in the methanol-acetic acid solution without the dye 
(90 ml of methanol:H20 (1:1 v/v) and 10 ml of glacial acetic acid), on a slowly
rotating platform for 4-8 hours at room temperature, changing the destaining solution 
three or four times destaining for 24 hours allows as little as 0.1 pg of protein to be 
detected as a single band.
After destaining, gels can be stored indefinitely in water or can be dried.
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4- RESULTS
The aim of this project is bacterial cloning and expression of BRCA2 
encoded proteins. The achievements and the results obatained in this study are 
summarized in a chronogical order. In figure 7 the structure of BRCA2 as 7 
overlapping fragments is shown.
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Figure-7: Fragments of BRCA2 gene.
• PCR amplification of E2, E3, E6 and E7 was accomplished
• E3, E6 and E7 were cloned into PCR-Script cloning vector
• Positive clones were selected and confirmed by restriction enzyme digestion
• Maxiprep plasmid preparation of pQE expression vectors were done
• pQE expression vectors were digested for subcloning and gel isolated
• Inserts in PCR-Script cloning vectors were digested and gel isolated
• Expression vectors and inserts were ligated and transformed into bacteria
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• Positive clones were selected
• E7 was further confirmed for expression studies
• Induction of bacteria harboring E7 was achieved and the recombinant 
protein was purified.
4.1 Polymerase chain reaction (PCR)
For cloning of BRCA2 fragments into pCR-Script SK (+) cloning vector, first 
of all 4 of the BRCA2 fragments were amplified (Figure 8, 9 and 10).
1 2  3
1300 bp  
1000 bp
Figure-8: PCR amplification of E2. Lane 1: 123 bp DNA ladder (Sigma), 
lane 2: Control PCR (1008 bp), lane 3: BRCA2 F2R2 (1301 bp), lane 4 : negative 
control.
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1000 bp
2 3
DO 840 bp
Figure 9: PCR amplification of E3. Lane 1 : 1 kb ladder (HT Ltd ), lane 2: 
BRCA2 F3R3 (840 bp), lane 3: BRCA2 F3R3 (840 bp)
2 3 4 5 6 7 8
1500 bp  
1000 bp 870 bp
Figure 10: PCR amplification of E2, E6 and E7. Lane 1 :1 kb DNA ladder 
(MBI), lane 2: BRCA2 F2R2 (1301 bp), lane 3: BRCA2 F5R5 (-), lane 4: BCA2 
F6R6 (1530 bp), lane 5; BRCA2 F7R7 (870 bp)
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These fragments are named as E2, E3, E6 and E7. The features of these 
fragments are summarized in table 14.
TabIe-14: The features of E2, E3, E6 and E7.
Primer Set Base numbers a.a numbers Template size T(A)
F2R2 (E2) 3691-4992 1154-1588 Genomic 1301 56
F3R3 (E3) 4708-5548 1495-1773 Genomic 840 52
F6R6 (E6) 8630-10160 2800-3311 cDNA 1530 57
F7R7 (E7) 9614-10485 3128-3418 cDNA 871 58
E2 and E3 were designed to amplify 1301 and 840 basepairs of DNA from 
exon 11 of BRCA2, so I used genomic DNA obtained from blood as the template. E6 
and E7 correspond to the C-terminal part of BRCA2 covering exons 19 to 27, so 
cDNA must be used for PCR reactions. I used cDNA that was obtained from a 
hepatocellular carcinoma cell line (Hep3BTR). These fragments were designed to 
amplify 1530 and 871 basepairs of DNA. In these amplifications Pfu DNA 
ploymerase was used since it was defined as the most accurate thermostable 
polymerase. The most important aspects of using Pfu polymerase is to allow 2 
minutes of extension time for every kb of amplified template. Pfu polymerase also 
lacks the nonspecific terminal transferase activity so produce blunt end fragments. 
Addition of non-template directed nucleotides is a common property of all 
thermostable polymerases except Pfu. Therefore, this high fidelity enzyme is a good 
choice for DNA amplifications in expression studies as well as the usage of amplified
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fragments with pCR-Script Amp SK (+) cloning kit where blunt end ligation is 
recomended.
In amplifications from genomic DNA, I tried the essence of 
Dimethylsulfoxide (DMSO) and saw that adding 5% DMSO of to the final volume of 
PCR reaction increases efficiency. In figure 11 the increased efficiency of PCR 
amplification by DMSO is shown.
1 2 3 4 5
1300 bp
1600 bp 
1000 bp
Figure 11: PCR amplification of E2 with and without DMSO. Lane 1: 123bp 
DNA ladder, lane 2: BRCA2 F2R2 (without DMSO), lane 3 : BRCA2 F2R2 (with 
5% DMSO)
After each PCR reaction I run 2-5% of the reaction volume on an agarose gel 
to qualitatively and quantitatively analyze the products. For direct cloning 
procedures, viewing the PCR result and cutting and purifying the specific band from 
agarose gels is essential, especially if multiple products were observed in the primary 
analysis.
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The amplifications of BRCA2 fragments were succesfiil with little or no non­
specific bands, at the expected sizes.
Purification of the PCR results were done either like described in the materials 
methods section or by using the MBI DNA extraction kit (#K0513), which utilizes 
the midified glass beads protocol of Vogelstein and Gillespie (1979) for recovering 
DNA from agarose gels. After purifying the specific band from agarose gel, 1 or 2(j,l 
of the recovered DNA must be run on an agarose gel to define the exact 
concentration of DNA since defining the concentration of DNA is essential for 
ligation reactions.
4.2 Cloning of the three different PCR fragments of BRCA2 into the 
pCR-Script cloning vector.
The PCR-Script cloning kit allows the easy ligation of blunt ended PCR 
products to PCR-Script cloning vector. The map and multiple cloning site of this 
vector is illustrated in figure 12.
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Figure 12: PCR-Script cloning vector and multiple cloning site (MCS). 
Multiple Cloning Site can be cleaved with following restriction endonucleases 
at the sites shown in paranthesis: Kpnl (657), Apal (663), Z)raII (660), Sail (674), 
Clal (684), HindlW (689), EcoRN (697), EcoRl (701), BamHl (719), Srfi (728), 
TVotl (738), Sad  (759).
pCR-Script AMP (SK+) cloning vector (Stratagene #211190) is supplied with 
a kit for allowing the direct cloning of Pfu polymerase amplified fragments. A novel 
Srfl site was generated in the muliple cloning site of pBlueScript AMP (SK+) vector 
to produce PCR-Script AMP (SK+) cloning vector. Srfi. is rare cutter which 
recognizes GCCCGGGC and cuts after GCCC, producing a blunt end. A more
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important feature of Srfi is the ability to work in the ligation mixture. The novel 
restriction site is cleaved by Srf{ during ligation, so the ligated vectors are freed for 
ligation with the insert. Another feature of this kit is to see the clones directly on the 
LB agar plate by blue/white selection. The lacZ gene is induced in the presence of 
IPTG and a colored byproduct is produced by the degradation of a galactose 
analogue X-Gal.
A typical ligation reaction contains 10 ng of predigested vector (1 ul), lOX 
ligation buffer (1 ul), 10 mM rATP (1 ul), Srfi restriction enzyme (1 ul, 5U), T4 
DNA ligase (lul, 4U), 100 ng insert and enough dH20 to add up to 10 ul.
The ligation reaction is completed in 1 hour in room temparature and it must 
be used immediately for transformation.
Epicuran Coli XI-1 Blue MRF’ Kan supercompetent cells, that were provided 
with the PCR-Script kit were used for transformations. Spreading 25 ul of 0. IM 
IPTG and 40 ul of 2% X-Gal (in dimethylformamide) onto LBA (LB agar) plate is 
essential for color selection. Since IPTG is toxic, spreading must be done 1 hour prior 
to inoculation of bacteria. It is also essential to incubate the transformants in SOC (or 
LB) medium without any selection for 45 minutes for the pre-induction of ampicilin 
resistance gene ( P-lactamase).
4.3 Minipreps of plasmid DNA
The transformed supercompetent cells produced lots of colonies on the plate 
of each transformation for BRCA2 fragments but the efficiency of transformation 
turned out to be not as much as stated in the manuel of the kit. Out of 87 white 
colonies investigated for the presence of vector+insert, only 6 were right. 
Conformation of the colonies were done by miniprep isolation of plasmid technique,
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which was previously defined in materials-methods section and illustrated in figures 
13, 14 and 15.
1 2 3 4 5 6 7 8
3000 bp
‘
3000 bp
' -v^.: v^-.vv·::; .,"■■· ■" „■ · :■ . , :  ■.
Figure 13: Clones from E3. Lane 1; 1 kb ladder (MBI), lane 2, Iane3, lane 
4, lane 5, lane 6, lane 7: white colonies selected fi-om the plate, lane 8: 1 kb ladder 
(MBI)
1 2  3 4 5 6 7 8 9  10 11 12
2500 bp
Figure 14: Clones from E6. Lane 1; 1 kb ladder (MBI), lane 2, lane3, lane 
4, lane 5, lane 6, lane 7, lane 8, lane 9, lane 10, lanell, lane 12: white colonies 
selected from the plate
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1 2 3 4 5 6 7
3000 bp  
2000 bp
Figure 15: Clones from E7. Lane 1, lane 2, lane3, lane 4, lane 5, lane 6:
white colonies selected from the plate, lane 7: 1 kb ladder (MBI)
4.4 Restriction analysis of plasmid DNA
Restriction analysis of plasmid DNA were done according to the specific 
restriction properties of inserts. Probable plasmids carrying an insert, unlike religated 
vectors, migrate slower and gave a different pattern. Such retarded plasmids were 
chosen for restriction. F3R3 containing vector is digested with BamHI and Hindlll. 
These restriction sites were artifically introduced to the ends of each primer so E3 
could be easily cut out of the vector. It is also important to know the orientation of 
the inserts, since they were obtained by blunt end ligation. The restriction results of 
plasmids are illustrated in figures 16, 17, 18, 19.
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2 3 4 5 6 7 8
1500 bp  
1000 bp
^Sm M
y ·  <
840 bp
Figure 16: Hindlll, BamHI/Hindlll digestion of probable clones of E3. Lane 
1: 1 kb ladder (MBI), lane 2; Hindlll cut of proable clone 1, lane3; BamHI and 
Hindlll cut of proable clone 1, lane 4; Hindlll cut of proable clone 2, lane 5; BamHI 
and Hindlll cut of proable clone 2, lane 6; Hindlll cut of proable clone 3, lane 7; 
BamHI and Hindlll cut of proable clone 3, lane 8: Hindlll cut of a plasmid obtained 
from a blue colony.
The result, although not very clear due to high RNA contamination, is good 
and the expected size of insert (840 bp) could be visualized. It is also probable to 
deduce the orientation of the clone since Hindlll digestion yield a bigger DNA 
fragment than the BamHI/Hindlll digestion. This size difference is due to the internal 
BamHI and Hindlll sites of PCR-Script (see MCS).
B: BamHI, H: Hindlll
The insert had been ligated in the orientation above and Hindlll digestion 
yields a 921 bp fragment, whereas BamHI and Hindlll digestion yields only 840 bp 
(exact size of insert).
1 2  3 4 6 7 8
3000 bp
1000 bp 
500 bp
616 bp
Figure 17: Hindlll restriction of probable clones from E7. Lane 1; 1 kb 
ladder (MBI), lane 5; BamHI and Hindlll cut of a plasmid obtained from a blue 
colony, lane 6: Hindlll cut of a plasmid obtained from a blue colony, lane 7; Hindlll 
cut of probable clone 1 (colony 5), lane 8; Hindlll cut of probable clone 2 (colony 6).
The results indicate that these clones have the same orientation and the 
expected size of Hindlll cut E7 is 616 bp (since there are internal Hindlll sites in E7).
H B B H H
688 719 728 872 983
■ vector PCR-Script
-insert (E7)
H
1599
B: BamHl H: HindlU
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2500 bp
3000 bp
870 bp
Figure 17: BamHI/SacI restriction of clones from E7. Lane 1: 1 kb ladder 
(MBI), lane 11; BamHI and Sad cut of clone 1, lane 12: BamHI and Sad cut of 
clone 2.
Since there are internal Hindlll sites in E7, it is convinient to cut with 
BamHI and another enayme in the MCS of PCR-Script. It is also important to find 
the other enzyme in the MCS of pQE, so subcloning could be achieved. The other 
enzyme was identified as Sad which allowed the isolation of total E7 as 880 bp.
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1500 b p ----------^
1000 bp
500 bp
3000 bp
Figure 19 :BamHI, BamHI/Hindlll restriction of probable clones 
from E6. Lane 1: 1 kb ladder (MBI), lane 2:BamHI cut of proable clone 9, Iane3; 
Hindlll cut of proable clone 9, lane 4: BamHI and Hindlll cut of proable clone 9, 
lane 5: BamHI cut of proable clone 10, lane 6; Hindlll cut of proabable clone 10, 
lane 7: BamHI and Hindlll cut of PCR-Script, lane 8: Hindlll cut plasmid obtained 
from a blue colony.
The results indicate that clone 9 has the right inset of size 1530 whereas 
clone 10 has lost its BamHI site. The orientation and the expected sizes of 
restrictions can be understood from the figure below.
H В H H H в
688 719 728 1019 1128
■ vector PCR-Script
2253
-insert (E7)
B: BamHI H: Hindlll
BamHI restriction of the plasmid must yield a 1539 bp fragment whereas 
Hindlll digestion will produce multiple bands but the visible one will be 1130 bp.
Ô1
Since the clones were ready, I began small scale and large scale preparation 
of the expression vector, pQE
4.5 Transormation and miniprep isolation of pQE
pQE is an expression vector which also allows the purification the expressed 
proteins by the 6XHis tag. Purification of mammalian proteins with the 6XHis tag is 
easy in bacterial sytems since 6XHis is not a common epitope of bacterial proteins. 
The purification is achieved by applying the cellular lysate into a Ni-NTA column and 
allowing the 6XHis tagged proteins to bind the column material. Nickel-6XHis 
interaction is very strong and the recombinat proteins are held in the column even 
under very stringent washing conditions (IM NaCl). Such an interaction could only 
be diminished by antagonizing the 6XHis tag, washing the column with imidazole. 
The plasmid map of pQE and the detailed multiple cloning site of pQE are illustrated 
in figures 20 and 21.
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Figure 20: The pQE expression vector
EcoRI/RBS 6xHis multiple cloning site to
p Q E -3 0  ■ ■ ■ ■ ■  ATG A G A G G A T C q · · · ·  - - ------ 1 AA'rTAGCTGAGES]
EeoRI/RBS 6xHis multiple cloning site to
pQ E -31 ■ ■ ■ ■ ■ ■  ATG AGAGrtATCd— AC I I AATTAGCIGAGESS
EcoRI/RBS 6xHis multiple cloning site
p Q E -3 2  mammm a t g  a g a g g a t c o · · · ·  - o ...............
to
] A A TTA G C TG A G Ea
Bam HI Sphl S a d  K pnl X m al S a il Pst I Hind III
GGATCCGC ATGCGAGCTCGGTACCCCGGGTCGACCTGCAGCCA VGCTT
Figure 21: The 6XHis tag and the MCS of pQE
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We had the DNA of pQE 30,31 and 32 and transformed them into DH5a so 
as to have large quantity of vector plasmid. The miniprep and the BamHI restriction 
results were summarized in figures 22 and 23.
3 4 5 6 7 8 9  10 11
3000 bp
Figure 22: Miniprep isolation of pQE. Lane 1: 1 kb ladder (MBI), lane 2: 
empty, Iane3; pQE 30, lane 4; pQE 30, lane 5: pQE 30, lane 6 pQE 31, lane 7; pQE 
31, lane 8: pQE 31, lane 9: pQE 32, lane 10: pQE 32, lanell; pQE 32
8 f
3500 bp
1 2 3 4 5 6 1  8
, f V . ■ , ,
f : - <1
'w  !■
Figure 23: BamHI restriction of pQE. Lane 1; 1 kb ladder (MBI), 
lane 2: pQE 30, lane3; pQE 30, lane 4: pQE 30, lane 5: pQE 31, lane 6 pQE 
31, lane 7: pQE 32, lane 8; pQE 32
The expected uncut size of pQE is 2500 bp (cut size is 3460 bp)
4.6 Purification of plasmid DNA by equilibrium centrifugation in 
caesium chloride-ethidium bromide gradients (Maxiprep)
After CsCl gradient centrifugation of plasmid DNA, we obtained about 2 mg 
of plasmid DNA dissolved in 1 ml of TE buffer. Applying lul of the results and lul of 
a previous miniprep, we saw the results in picture 24.
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Figure 24: Maxiprep isolation of pQE. Lane 1: 1 kb ladder (MBI), lane 2: 
pQE 30 maxiprep, lane3: pQE 30 miniprep, lane 4: pQE 31 maxiprep, lane 5; pQE 
31 miniprep, lane 6 pQE 32 maxiprep, lane 7: pQE 32 miniprep
4.7 Subcloning of the BRCA2 fragments into the expression vector pQ£
For subcloning BRCA2 fragments into pQE expression vector I made 
midipreps of the E3, E6 and E7 PCR-Script constructs and cut them with appropriate 
restriction enzymes. It is also very important to put these fragments in frame for 
expression so right pQEs were identified to be pQE32 for E3 and pQE31 for E6 and 
E7. These fragments are gel purified and the restriction results of pQE 31 and 32 and 
E3, E6 and E7 are shown in figures 25, 26 and 27.
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Figure 25: Restriction results of pQE31 and PQE32. Lane 1: 1 kb ladder 
(MBI), lane 2 and Iane3; pQE 31 BamHI/Hindlll cut, lane 4 and lane 5: pQE 32 
BamHI/Hindlll cut, lane 6 and lane 7: pQE 31 BamHI/SacI cut, lane 8; 
mindlll/EcoRI digest (MBI).
These fragments were cut out of the gel and purified from agarose.
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3000 bp 
1500 bp
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900 bp
Figure 26: Restriction results of E6 and E7. Lane 1; 1 kb ladder 
(MBI), lane 2 and laneS; E6 clone 10 BamHESacI cut, lane 4 and lane 5: E6 
clone 9 BamHESacI cut, lane 6 and lane 7; E7 clone 1 BamHESacI cut, lane 
8: mindlll/EcoRI digest (MBI)
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Figure 27: BamHI/Hindlll digestion of E3 and BamHI/SacI digestion 
of E6. Lane 1: E3 clone 1 Bam HI/Hindlll cut, lane 2: E6 clone 9 
BamHI/SacI cut, Iane3; E6 clone 9 BamHI/SacI cut, lane 4; E3 clone 1 Bam 
HI/Hindlll cut
I had high amount, pure DNA for transformation after the gel purifications of 
these products. Concerning 1:10 vector: insert ratio, ligation reactions were set as 
described in materials-methods section. Our final aim is to express and purify the 
proteins encoded by this fragments. For this reason the choice of the host bacteria is 
very important. JM109 was offered to propogate the pQE vectors and M l5 was 
offered for expression studies. JM109 was transformed with the ligation mixtures so 
as to propogate the expression constructs. The transformation or the ligation 
efficiency was very low, so we could obtained only a few colonies for each 
transfromation. Only 1 colony appeared in the transformation of E7, 3 colonies 
appeared in the trasformation of E6 and 13 colonies appeared in the transformation of 
E3. All of the colonies in E7 and E6 were conformed to be positive whereas 2 of the 
11 colonies in E3 were positive.
8 8
4.8 Miniprep results of E3, E6 and E7
The miniprep results of E7, E6 and E3 are summarized in the figures 28,29
and 30.
1 2 3 4 5 6 7
3000 bp
Figure 28: Transformation result of E7 and miniprep. Lane 1; 1 
kb DNA ladder (MBI), lane 2: miniprep of the E7 in pQE, laneS. uncut 
empty pQE vector
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3500 bp
Figure 29: Miniprep results of E6. Lane 1: XHindlll/EcoRI digest 
DNA ladder, lane 2: miniprep of QE 30, lane3, lane 4, lane 5: miniprep of 
E6
3 4 5 6 7 8 9 10 11 12’V ,r  ^ .
3500 bp
2000 bp
Figure 30: Miniprep results of E3. Lane 1: X,HindIII/EcoRI digest 
DNA ladder (MBI), lane 2, Iane3, lane 4, lane 5, lane 6, lane 7, lane 8, lane 
9, lane 10, lanell; miniprep of all the colonies of the plate.
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With the results obtained I have concluded the cloning of fragments into pQE 
and start expression studies. I made a fresh transformation with E7 in pQE and 
restrict the miniprep result for assuring the correct insert and for having fresh colonies 
for expression..
4.9 Restriciion of E7 in pQE
The probable plasmid containing the E7 is digested with BamHI and 
Hindlll for conformation. Since there are internal Hindlll sites in E7, it is 
expected to give a 616 bp fragment. The restriction of E7 in pQE is shown in 
figure 31.
1 2 3 4 5
1000 bp  
500 bp
616 bp
Figure 31: Restriction of E7 in pQE. Lane LModified 1 kb DNA 
ladder (MBI), lane 2; E7-1 restricted with BamHI, Iane3 E7-2 restricted with 
BamHI, lane 4 E7-2 restricted with BamHI and Hindlll, lane 5: BamHI cut 
pQE31
9 1
The expected size of BamHI/Hindlll digest of the insert is 616 bp.
4.10 Induction of C-terminal of BRCA2 expression by IPTG
After being sure about the insert, I transformed E7 in pQE into Ml 5. Picking 
fresh colonies from the plate, I have incubated them in LB amp, kan. As the OD. of 
inoculate reaches 0.7-0.9,1 induced them with 0.4-2 mM IPTG. The induction results 
in 5 hours. Then the cells were ready to lyse and isolate proteins.
The expression of a recombinant protein depends on some factors, including 
the size, solubility and the toxicity of the protein. Even the expression pattern of 
different parts of a same protein may differ due to the aminoacid content, size and 
solubility. Insoluble proteins can form inclusion bodies if expressed in high amounts. 
Foreign and highly expressed proteins are also targets of intracellular proteases and 
degraded either in the cell or during the lysis of the cell.
I have expressed E7 in bacterial system. The trials to view the expression 
SDS-PAGE didn’t gave any positive result and I could not see any band getting dark 
or thick after induction. This can be due to the degradation of the protein or the high 
basal expression.
Since 6XHis tag is very rare in bacteria, it is also plausible to purify the 
protein and check the size. I purified the protein in denaturing and non-denaturing 
conditions with the methods described in materials-methods section and able to see a 
very specific band at the expected size (39 kDa). Although E7 in pQE codes for a 
301 aminoacid fragment, the molecular weight calculations showed that it codes for 
a 39 kDa. protein. The SDS-PAGE results of protein purification is illustrated in 
figure 32.
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Figure 32: SDS-PAGE results of purified protein fragments. Lane 1: 66 kDa 
and 45 kDa protein size marker, lane 2: 500 mM imidazole fraction of purified E7 
(clone 1), ІапеЗ; 250 mM imidazole fraction of purified E7 (clone 1), lane 4: 250 
mM imidazole fraction of purified E7 (clone 2), lane 5: 250 mM fraction of purified 
E7 (see below), lane 6: 500 mM imidazole fraction of purified E7 (see below), lane 
7: Flowthrough, lane 8. total lysate, lane 9; Flowtrough , lane 10: Wash 1, lanell; 
Wash 2, lane 12; 20 mM imidazole wash, lane 13: 250 mM imidazole fraction of 
purified E7, lane 14: 500 mM imidazole fraction of purified E7, lane 15: 45 kDa and 
34 kDa protein size marker.
The fractions at lane 5 and 6 were purified under non denaturing conditions.
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5- DISCUSSION and FUTURE PERSPECTIVES
The studies presented in this thesis describe the bacterial cloning and 
expression of BRCA2 encoded proteins and subsequent purification of the C-terminal 
region (E7).
BRCA2 gene is a novel tumor supressor gene which is mutated in at least 40% 
of familial breast cancer cases (Marcus et al. 1996). It is composed of 27 exons, of 
which the first one is non-coding (Tavtigian et al. 1996). BRCA2 gene codes for a 
3418 aminoacid polypeptide which is thought to be 390-424 kDa. Till its 
identification and cloning (Wooster et al. 1994, Wooster et al 1995), lots of studies 
were done concerning the mutation spectrum among familial and sporadic breast 
cancers. There are more than 70 mutations identified in BRCA2, mostly destrupting 
the reading fi-ame and producing immature stop of translation. There are recurrent 
mutations defined in closed populations like 999 del 5 in Iceland (Thorlacius et al. 
1996) and 6147 del T in Ashkenazi Jews (Couch FJ. et al. 1996), but the other 
mutations found in random high risk breast/ovarian cancer families are targeting all 27 
exons except the extereme 3 prime (3’) 26*** and the 27*** exons. Due to the constant 
loss of a minimal 200-250 amino acid fragment of BRCA2, the C-terminal region was 
assumed to carry out some important functions. The identification of a granin domain 
in the minimal loss region led proposals that BRCA2 protein could be secreted and 
exhibits properties of granin ( Jensen et al. 1996). However this proposal was ruled 
out by the identification of a polymorphic stop codon leading the production of 
functional BRCA2 without the granin domain (Mazoyer et a l 1996). The significance
of the putative granin domain is not determined for now. There are two more reports 
defining the domains of this novel protein. These include the definition of a jun 
homology region at exon 3 (Milner et al. 1997) and identification of 8 conserved 
repeats in exon 11 with unknown function (Bork et al. 1996).
There are no proteins defined to confer a significant homology to BRCA2 but 
the number of exons, distribution through genomic DNA, having a huge exon 11 and 
the high incidence of mutations in familial breast cancer presumes a similarity with 
BRCAl. The similarities with BRCAl also includes a common protein-protein 
interaction. Both BRCAl and BRCA2 were shown to bind the bacterial RecA 
homologue of eukaryotic RadSl protein (Sharan et al. 1997). It is of importance to 
figure out that the C-terminal region (aminoacids 3196-3232) of BRCA2 is essential 
for this interaction. The similarities between BRCAl and BRCA2 suggested these 
proteins to be redundant, but they were associated with different phenotypes of high 
risk breast cancer families. Families with male breast cancer are extremely linked to 
BRCA2 whereas families with multiple breast and ovarian cancer are more linked to 
BRCAl.
Important proteins, such as DNA repair proteins are evolutionary conserved. 
The embrionic lethality of BRCA2 defines an important role for BRCA2 but BRCA2 
is not a well conserved protein. It confers a 59% homology with mice and the 
percentage gets lower with pig, dog and swine. The identification of the 8 conserved 
repeats in BRCA2 and the same conserved repeat in C. elegans may show the 
importance of BRCA2 throuhout the evolution (Bignell et al. 1997). It could be 
intersting to study a breast cancer predisposing gene in marsupials, birds, reptiles, fish 
and yeast.
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All of the tumor supressors identified for which are taking a role in cell cycle, 
like p53 and Rb, negatively regulate cell proliferation. In knock out and in vitro 
studies BRCA2 was mostly associated with cell proliferation. In the absence of 
BRCA2, cell proliferation is mostly inhibited and BRCA2 knock out mouse embryos 
can not develop fully to bom. BRCA2 may define a novel kind of tumor supression 
action which was seen in other tumor supressor genes (Sharan et al. 1997).
Protein-protein interactions and post-tanslational modifications define another 
aspect of proteins which give clues for the function. Only MmRadSl protein was 
cofirmed to bind BRCA2 (Sharan et al. 1997) and a phosphorylation at tyrosine 42 
was proposed (Milner et al. 1997). If BRCA2 is identified to interact with proteins of 
known functions, its cellular roles could be more precisely predicted.
For identification of the unknowns that I summarized above purified BRCA2 
protein fragments and antibodies against specific regions of BRCA2 are essential. As 
a optimization step of this study I cloned 3 BRCA2 fragments into an expression 
vector and expressed and purified a 39 kDa protein corresponding to the extereme C- 
terminus of BRCA2 protein.
The pQE expression system allows high expression and easy purification with 
the 6XHis tag attached to the N-terminal of the peptide and the Ni-NTA based 
affinity chromatography. Although 6XHis-Ni-NTA binding is very strong and specific, 
there are some limitations in protein purification studies. Such difficulties include the 
limited expression capacity of bacterial system (maximum 100-120 kDa), the 
solubility and the toxicity of the expressed protein and preserving the 3 dimensional 
shape and activity of purified proteins. Purifying under denaturing conditions is better 
since the 6XHis tag is more exposed and more proteins could be purified with this 
system if enzymatic activity is not essential. Proteins purified under denaturing
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conditions could be used in antibody production. It is of essense to purify in non­
denaturing conditions if enzymatic activity and 3 dimensional shape is important. 
Protein-protein interactions and kinetic assays could be accomplished only with 
proteins purified under non-denaturing conditions. I must also note that even the 
fragments of a large protein can confer different chracteristics and expression and 
purification strategies must be developed for each polypeptide.
The number of antibodies against BRCA2 (which are polyclonal) is very 
limited for now and their specificity is a question to be determined. The expression of 
BRCA2 as 7 overlapping and combinable fragments will allow the generation of 
antibodies against specific regions of protein. The antibodies, especially against the C- 
termial (E7) of the protein could also be used in identification of the mutant BRCA2, 
which lacks a minimal 250 aminoacid fragment in mutant form.
The 6XHÍS tag also provides an experimental advantage in in vitro protein 
interaction assays. Proteins bound to BRCA2 could be co-purified with the help of the 
6XHÍS tag and Ni-NTA affinity chromatography. Most of the proteins have known 
protein-protein interactions at their C-terminal (dimerization, tetramerization) and 
transcription activation domains at their N-terminal region. Proteins binding to the last 
290 aminoacid portion of BRCA2 could be identified by the help of 6XHis tagged 
E7.
As a future perspective I want to optimize and express whole BRCA2 as 
fi'agments and produce specific antibodies against them as well as study the proteins 
interacting with BRCA2.
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